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Abstract 
 
 
Widespread occurrence of pharmaceuticals residues (ng/L to µg/L) has been 
reported in aquatic ecosystems. However, their toxic effects on aquatic biota and 
environmental risks remain unclear. Generally, the acute toxicity towards non-target 
organisms has been assessed in laboratory experiments, while chronic toxicity 
studies have rarely been performed. Of importance appears also the assessment of 
mixture effects, since pharmaceuticals never occur in waters alone.  
The aim of the present work is to evaluate acute and chronic toxic response in the 
crustacean Daphnia magna exposed to single pharmaceuticals and mixtures.  
We tested fluoxetine, a selective serotonin reuptake inhibitor widely prescribed as 
antidepressant, and propranolol, a non selective β-adrenergic receptor-blocking 
agent used to treat hypertension.  
Acute immobilization tests and chronic reproduction tests were performed according 
to OECD guidelines 202 and 211, respectively. Single chemicals were first tested 
separately. Toxicity of binary mixtures was then assessed using a fixed ratio 
experimental design. Five concentrations (0.5, 0.71, 1, 1.41, 2 Toxic Units) and 5 
percentages of each substance in the mixture (0, 25, 50, 75 and 100%) were tested 
for a total of 26 experimental conditions, including the negative control. Six replicates 
for each treatment were carried out. The conceptual model of Concentration Addition 
(CA) was adopted in this study, as we assumed that the mixture effect mirrors the 
sum of the single substances for compounds having similar mode of action. The 
MixTox model was applied to analyze the experimental results. This tool evaluates if 
and how observed data deviates from the CA model, and tests if significantly better 
descriptions of the observed data can be achieved using a set of deviation functions. 
These functions allow a differentiation between synergism and antagonism, along 
with deviations based on the dose-level and chemical ratio dependency. Results 
showed a significant deviation from CA model that indicated antagonism between 
chemicals in both the acute and the chronic mixture tests.  
The study was integrated assessing the effects of these compounds with a battery of 
biomarkers. We wanted to evaluate the organism biological vulnerability caused by 
low concentrations of pharmaceutical occurring in the aquatic environment. Indeed, 
biomarkers are early warning signals able to inform about alteration in health status 
of organism before life cycle traits are compromised.  We evaluated three biomarkers 
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in response to a sub-chronic exposure of Daphnia magna to fluoxetine. We assessed 
the acetylcholinesterase and glutathione s-transferase enzymatic activities and the 
malondialdehyde production. No treatment induced significant alteration of 
biomarkers with respect to the control. 
Biological assays and the MixTox model application proved to be useful tools for 
pharmaceutical risk assessment. Although promising, the application of biomarkers in 
Daphnia magna needs further elucidation. 
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1. Introduction 
 
 
1.1 Pharmaceuticals as emerging contaminants 
 
Pharmaceuticals, in addition to their important role in health care (Brun et al., 2006), 
are addressed to as a new class of widespread environmental pollutants. 
Pharmaceuticals belong to the group of PPCPs (Pharmaceuticals and Personal care 
Products) found in the environment. PPCPs comprise a very broad, diverse collection 
of thousands of chemical substances, including prescription, veterinary, and 
therapeutic drugs, antibiotics, vitamins, but it includes also cosmetics, fragrances, 
shampoos, soaps, toothpastes, and sunscreens. The acronym "PPCPs" was coined 
in the 1999 and then has become an adopted term used in both the technical and 
popular literature.  
Pharmaceuticals enter into aquatic environments via biomedical, veterinary medicine, 
agricultural, and industrial routes (Jorgensen and Halling-Sørensen, 2000) (Fig.1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1. Origins and fate of pharmaceuticals and personal care products (PPCPs) in the environment (Source: EPA) 
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The biomedical route via human sewage is perhaps the main path that 
pharmaceuticals follow to enter in the environment. Once pharmaceuticals are 
ingested, they are partially excreted in a biologically active form, either as the parent 
substance or as an active metabolite (Calamari et al., 2003). Because of incomplete 
elimination in wastewater treatment plants, residues of pharmaceuticals and their 
metabolites occur in surface waters (Fent et al., 2006). 
The result is that the waterways of all over the world are exposed to a cocktail of 
chemicals ranging from β-blockers to steroidal hormones, from analgesics to 
neuroactive compounds (Fig. 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Fig. 1.2. Concentration of pharmaceuticals in treated wastewater (a) and surface water (b) (source: Fent et al., 2006) 
Pharmaceuticals are ubiquitously present in rivers, lakes, and in marine coastal 
waters and occasionally were found in ground and potable waters (Fent et al., 2006). 
Since pharmaceuticals are designed to target specific metabolic and molecular 
pathways in humans or animals (veterinary usage), when introduced into the 
environment they may affect the same or comparable pathways in vertebrates and 
invertebrates having identical/similar targets (Christen et al., 2009).  
Only little information is available about ecotoxicological effects of pharmaceuticals 
on aquatic and terrestrial organisms and wildlife. Numerous scientific studies have 
documented a range of detrimental impacts of pharmaceuticals upon freshwater 
ecosystems, in particular, adverse effects on fish developing sexual and behavioral 
abnormalities such as males producing eggs or females disinclined to spawn. 
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Perhaps the most famous case was detected in the Washington basin where in 2003, 
during health assessments conducted in response to kills and a high prevalence of 
skin lesions observed in smallmouth bass Micropterus dolomieu in the South Branch 
of the Potomac River, the presence of immature oocytes within testes was noted 
(Blazer et al., 2007) and scientists started to indagated on fish intersex and testicular 
oocytes (TO) usually indicators of exposure to estrogenic compounds. Thus, the 
scientific consensus is that pharmaceuticals threaten aquatic organisms 
(www.cicleofblue.org), though the effects on humans drinking contaminated water or 
eating contaminated food are not as clear. 
Standard acute ecotoxicity data have been reported for a number of 
pharmaceuticals, however, such data alone may not be suitable for specifically 
addressing the question of environmental effects, and subsequently evaluating the 
hazard and risk (Fent, 2003). That is due firstly to the normally trace-level 
environmental concentrations of pharmaceuticals, usually in the range of ng/L, that 
means that toxicity testing endpoints may not be sensitive enough to characterize 
adequately the risk associated with these chemicals (Brooks et al., 2003). Although 
ecotoxicological studies agree that pharmaceuticals residues concentrations in 
surface water generally do not cause acute toxicity to aquatic organisms, as their 
environmental concentrations are typically too low, the continuous discharge exposes 
non-target aquatic organisms such as Daphnia magna continuously through the life 
cycle for multiple generation. Moreover, although they can be degraded in the 
environment by biotic (Winkler et al., 2001) or abiotic process (Andreozzi et al., 
2002), it is assumed that pharmaceuticals could act as persistent compounds simply 
because of their continual infusion into aquatic media via Sewage Treatment Plant 
(STP) effluents, which sustain a multigenerational exposure for the resident 
organisms (Daughton and Ternes, 1999). Even slight, non significant influences on 
single components which would not result in any acutely discernible effect, with 
regulatory cascades, might ultimately affect a whole population by their negative 
consequences on fitness: disturbances in hormonal homeostasis (endocrine 
disruption), immunological status, signal transduction or gene activation, for example 
(Seiler, 2002).  
Another item to take in consideration is that the majority of ecotoxicological studies in 
the aquatic and terrestrial environments focus mainly on the toxicity of single 
compounds in controlled conditions (Barata et al., 2006) and relatively few studies 
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have examined sublethal or mixture response effects. Studies have demonstrated 
that a chemical will rarely be found alone in the environment but commonly in 
combination with others, thus in order to evaluate in a more realistic way the effects 
of contaminants when they occur in the environment, researches should provide 
studies on pharmaceuticals mixtures. 
Since pharmaceuticals are designed with the intention of performing a biological 
effect (Henschel et al., 1997), this concept may be very important for these specific 
substances in terms of fate and effects toward non-target organisms in the 
environment, even at low concentrations (Ferrari et al., 2003). Unfortunately, until 
now, there is very little information about the chronic toxicity, and the potential 
bioamagnification  of pharmaceuticals along the food chains. Since pharmaceuticals 
are present in water bodies throughout the world, although no studies have shown a 
direct impact on human health and studies are still in progress to determinate the 
environmental impacts, the lack of information cannot rule out the possibility of 
adverse outcomes due to interactions or long-term exposures to these substances. 
Certainly, the scientific evidence merits new safeguards for freshwater ecosystems. 
 
 
1.1.1 Pharmaceuticals in the environmental legislation 
 
Data from 2008 describes a slight increases in the market for pharmaceutical 
substances in Europe and due to the rising average age of the population in Europe, 
consumption of pharmaceuticals is expected to rise again in the next years. 
Since it was demonstrated that, although at low concentrations, pharmaceutical 
residues and their metabolites are present in freshwater worldwide, gain new 
knowledge on effects of them to the aquatic organisms is necessary. Unfortunately 
there is a significant lack of knowledge about effects of pharmaceuticals on aquatic 
organisms.  
Although further research is needed, our general understanding on pharmaceutical 
ecotoxicity has improved in recent years, when governments started to recognize 
pharmaceuticals resides as a potential problem concerning public health. 
Thus, in the last years, different US regulatory agency as The Drug Enforcement 
Administration (DEA), the Food and Drug Administration (FDA), and the 
Environmental Protection Agency (EPA) have all taken steps to address 
pharmaceutical residues in both the community and institutional settings: 
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 Several regulations proposed by the Drug Enforcement Administration (DEA), a 
division of the US Department of Justice, hold the potential to affect members of 
industry, and in particular the pharmaceutical industry. One such proposed rule, 
Disposal of Controlled Substances, proposes to require a system in which 
manufacturers and users would need to secure leftover or otherwise unused 
controlled substances (any scheduled substance under the Controlled 
Substances Act, or CSA) for proper disposal. The regulation is required under the 
terms of the Secure and Responsible Drug Disposal Act of 2010, and DEA has 
already sought opinions from industry in the form of a January 2009 Federal 
Register notice in which it called for  "options for the safe and responsible 
disposal of dispensed controlled substance." An electronic copy of this document 
is also available at the http://www.regulations.gov website. 
 The White House Office of National Drug Control Policy with input of the Food 
and Drug Administration (FDA) provided guidelines on pharmaceuticals disposal 
and good manufacturing practice. The guidance is a compilation of 
pharmaceuticals regulations primarily directed to drugmakers and consumers.  
 EPA oversees implementation of the Resource Conservation and Recovery Act 
(RCRA), which is a federal law controlling the management and disposal of solid 
and hazardous wastes. EPA proposed in 2008 to add pharmaceuticals to the 
Universal Waste Program governing waste disposal, but has since declined to 
finalize that proposal. EPA published a new proposed regulation in summer 2013 
intended to govern the disposal of pharmaceutical waste generated by health 
care facilities. 
 
In Europe, the need to report any potential environmental risk related to the use of 
medicinal products was addressed for the first time in 1993 with Directive 93/39/CEE. 
The environmental aspects of the pharmaceuticals were taken in consideration by the 
European Medicines Agency (EMA), the REACH regulation, and the Water 
Framework Directive (FWD): 
 The EMA introduced the principle of the environmental risk assessment for all 
new drugs before effecting registration. The European Medicines Agency 
(formerly known as the European Agency for the Evaluation of Medicinal 
Products EMEA), is the European Union agency for the Evaluation of Medicinal 
Products. The foundation of EMA (http://www.ema.europa.eu/ema/) in 1995 with 
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the financial assistance of the European Union and the pharmaceutical industry, 
was intended to harmonize (but not replace) the work of national regulatory 
bodies in terms of pharmaceuticals; in analogy to what was already the Food and 
Drug Administration. The agency in 1997 published the first guidelines for the 
environmental risk assessment of veterinary drug, and the first draft of the 
guidelines of the environmental risk assessment of medicines for human use 
were more belatedly published in 2001. According to the guidelines, "applications 
for authorization to the marketing of pharmaceutical products for human use must 
be accompanied by an Environmental Risk Assessment (ERA). "It determines an 
obligation on the environmental risk assessment for new medicinal products for 
which is required marketing authorization in the European Union. If a 
pharmaceutical is recognized as dangerous for the environment its production 
will be stopped. If the procedure can not exclude the possibility of a risk to the 
environment related to the test substance (active substance and/or metabolites), 
the procedure requires the adoption of a series of precautionary and safety 
measures, designed to mitigate the exposure of the environment to the new 
pharmaceutical. In particular, special labeling requirements, with an indication of 
the potential environmental risks posed by the medicinal product to be described 
on the label, and that should be reported in the "Summary of Product 
Characteristics" and the package leaflet of the medicinal product, with an 
indication of special precautions that must be followed for the storage and 
administration to patients with the aim to promote the proper disposal and 
minimize improper disposal of medication in the environment, informing the 
patient and the medical staff on the potential environmental risks related. The 
guidelines recommend that the package leaflet or the packaging of drugs, all 
drugs but especially those for which we can not exclude a potential 
environmental risk, bring back the following sentence: "to protect the environment 
and reduce pollution environmental, unused or expired products should not be 
disposed of with normal garbage or to sewer, but must be returned to the 
pharmacy”.  
The EMA guidelines will govern the environmental risk in relation to new drugs 
for human use, for now nothing is planned with regard to drugs already on the 
market to the entry into force of the Regulation, in particular in the field of 
pollution of water bodies. 
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 REACH (Registration, Evaluation and Authorization of Chemicals) is based on 
the principle that industry should manufacture, import, use substances or place 
them on the market in a way that, under reasonably foreseeable conditions, 
human health and the environment are not adversely affected. In order to ensure 
this, manufacturers and importers need to collect or generate data on the 
substances and assess how risks to human health and the environment can be 
controlled by applying suitable risk management measures. To prove that they 
actually meet these obligations, as well as for transparency reasons, REACH 
requires manufacturers and importers to submit to the European Chemicals 
Agency (ECHA) a registration dossier containing a technical dossier including 
data on the substance and, for substances in quantities of 10 tonnes or more per 
year per registrant, a chemical safety report assessing how risks to human health 
and the environment can be controlled (http://www.prc.cnrs-
gif.fr/reach/en/registration_obligation.html). Generally, they apply to all individual 
chemical substances on their own or in preparations. Substances falling under 
the scope of the REACH regulation and not exempted from the registration 
obligation must be registered before they can be manufactured or imported into 
the European Union. Some substances are completely excluded from REACH 
and waste is also excluded as it is not a substance, a preparation or an article 
within the meaning of REACH. They are considered as causing minimum risk to 
human health and the environment (substances listed in annexe IV) or their 
registration is deemed inappropriate or unnecessary (substances or processes 
listed in annexe V). In base of REACH regulation chemical preparations such as 
paints (which include such solvents, dyes, and other elements that confer 
particular characteristics of the product) detergents and cosmetics are included in 
the regulation, but pharmaceuticals while being of chemical preparations are 
excluded from the REACH. 
 In 2012 a proposal to implement the WFD on pharmaceuticals residues has been 
put forward. The Water Framework Directive (Directive 2000/60/EC of the 
European Parliament and of the Council of 23 October 2000 establishing a 
framework for Community action in the field of water policy) is a European Union 
directive which commits European Union member states to achieve good 
qualitative and quantitative status of all water bodies (including marine waters up 
to one nautical mile from shore) by 2015. It is a framework in the sense that it 
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prescribes steps to reach the common goal rather than adopting the more 
traditional limit value approach. The ecological and chemical status of surface 
waters are assessed according to the following criteria: 
 Biological quality (fish, benthic invertebrates, aquatic flora); 
 Hydromorphological quality such as river bank structure, river continuity 
or substrate of the river bed; 
 Physical-chemical quality such as temperature, oxygenation and nutrient 
conditions; 
 Chemical quality that refers to environmental quality standards for river 
basin specific pollutants. These standards specify maximum 
concentrations for specific water pollutants. If even one such 
concentration is exceeded, the water body will not be classed as having 
a “good ecological status”.  
 
Article 14 of the directive requires member states "to encourage the active 
involvement of interested parties" in the implementation of the directive.  
Article 16 of the Water Framework Directive (2000/60/EC) (WFD) sets out 
"Strategies against pollution of water", outlining the steps to be taken. In 2001 
was established a first list of priority substances to become Annex X of the WFD. 
These substances were selected from amongst those presenting a significant risk 
to or via the aquatic environment. This first list was replaced by Annex II of the 
Directive on Environmental Quality Standards (Directive 2008/105/EC) (EQSD), 
also known as the Priority Substances Directive, which set environmental quality 
standards (EQS) for the substances in surface waters (river, lake, transitional and 
coastal) and confirmed their designation as priority or priority hazardous 
substances, the latter being a subset of particular concern.  As required by the 
WFD and EQSD, the Commission subsequently reviewed the list in 2008 and in 
2012 and it put forward a proposal for a Directive amending the WFD and the 
EQSD as regards priority substances. According to Annex V, point 1.4.3 of the 
WFD and Article 1 of the EQSD, good chemical status is reached for a water 
body when it complies with the EQS for all the priority substances and other 
pollutants listed in Annex I of the EQSD. The Water Framework Directive 
foresees an obligation to regularly review the list of priority substances, a review 
of the priority substances provisions has to be done at least every four years. The 
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list have been established by Decision No 2455/2001/EC and Directive 
2008/105/EC and the priority substances were 33 at this point. Following a 
comprehensive consultation and assessment process, the Commission proposal 
of 31 January 2012 foresees the inclusion of further 15 priority substances 
(http://ec.europa.eu/environment/water/water-dangersub/pri_substances.htm), 
amongst them substances used in pesticides and biocides, combustion by-
products and, for the first time, pharmaceutical substances, as well as 
designation of further priority hazardous substances (unfortunately, as will be 
explained below, this has remained only a proposal for pharmaceuticals). For six 
of the 15 new priority substances the classification proposed would require their 
emissions to water to be phased out within 20 years. The proposal also includes 
stricter standards for four currently controlled substances, and a requirement to 
phase out the emissions of two others already on the list. The proposed 15 
additional priority substances are: 
 Plant protection product substances: Aclonifen, Bifenox, Cypermethrin, 
Dicofol, Heptachlor, Quinoxyfen; 
 Substances used in biocidal products: Cybutryne, Dichlorvos, Terbutryn; 
 Industrial chemicals: Perfluorooctane sulfonic acid (PFOS), 
Hexabromocyclododecane (HBCDD); 
 Combustion by-products: Dioxin and Dioxin-Like PCBs; 
 Pharmaceutical substances: 17 alpha-ethinylestradiol (EE2), 17 beta-
estradiol (E2), Diclofenac; pharmaceuticals are proposed for the first time. 
 
In July 2013 the European Commission (EC) with Directive 2013/39/EU has 
added 12 new substances to its priority list of 33 known pollutants in the latest 
priority list of chemicals known to pose a risk to the safety of surface waters. In 
addition, for the first time, the EC has placed three pharmaceuticals on a ‘watch 
list’ of emerging aquatic pollutants that may be added eventually to the priority list 
later (http://www.euractiv.com/health/new-chemicals-pharmaceuticals-ad-news-
529073). The three chemicals are diclofenac, a commonly-used generic anti-
inflammatory painkiller which is suspected of killing fish, and the hormones 17 
alpha-ethinylestradiol (EE2) and 17 beta-estradiol (E2), which the EC claims can 
disrupt the endocrine system in humans and harm fish reproduction. 
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Richard Seeber, the Austrian Member of European Parliament (MEP) hailed the 
addition of pharmaceuticals to the list, predicting that water policy is a long-term 
policy and it will be a very interesting field in the future because our waters are 
unfortunately increasingly burdened with pharmaceuticals.  
Adding them to the watch list is a partial victory for the pharmaceutical industry, 
which had lobbied to remove the pharmaceutical ingredients from the WFD 
altogether, arguing that the data behind the EC's claims was not robust enough 
to warrant action. This list allows pharmaceutical residues not to be controlled in 
water until a further revision of the list comes about, meaning that control 
mechanisms for these substances could be in place as far as in 2027 (year of the 
extension of the deadline for achieving water quality targets) and  from 2021 to 
2027 they could be the new additions to the list. That has been a missed 
opportunity for the European Parliament to send out a clear message that 
significant negative impacts on freshwater and marine ecosystems and ultimately 
humans is caused by pharmaceutical substances and other emerging pollutants. 
 
European Federation on National Association of Water Services (EUREAU) has 
commented the implementation of the WFD considering the need to tackle water 
pollution by chemical and pharmaceutical substances at the source and not in 
treatment plants for drinking water or in waste water treatment plants, which 
should be the last resort. It proposed the inclusion of a new article in the WFD 
which will seek to develop a strategic approach to pollution of water by 
pharmaceutical substances aimed at reducing their discharges, emissions, and 
losses to the aquatic environment. It is true that upgrading wastewater treatment 
plants with advanced techniques that would remove not only pharmaceuticals but 
also other micropollutants can be costly, but there are simple and low cost 
upstream measures already in use in different Member States (MS) such as 
collection schemes for unused pharmaceuticals that EU legislation already 
requires MS to implement; encouraging design of green pharmaceuticals that are 
fully metabolized in the body and rapidly biodegrade in the environment into 
harmless compounds; and educating healthcare professionals to optimize 
medicines prescription behavior so that only the right amount of pharmaceuticals 
needed is prescribed, giving priority to the least environmentally hazardous 
medicines. 
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1.2 Mixtures toxicity  
 
Chemicals of anthropogenic origin, arising from an urban, industrial or agricultural 
use, usually are found  in the environment in combination with other substances, 
therefore we need to study combined effects of mixtures of two or more chemicals to 
determinate what happens in nature in a more realistic way compared to when 
toxicants are tested individually. Pharmaceutical residues, as all other chemicals, 
occur as mixture in the environment, therefore it is important to study the effect of a 
pharmaceutical in combination with another, both abundantly present in freshwater.  
Pharmaceuticals in mixture can produce an interaction effect, i.e. synergistic or 
antagonistic effect. In toxicology, synergism is when organisms are exposed to two or 
more chemicals at the same time and the toxic effects are greater than the sum of 
the effects of the single pharmaceuticals. It can be explained as 1+1 > 2. On the 
other hand antagonism is the opposite of synergism. It is the situation where the 
combined effect of two or more compounds is less toxic than the sum of the 
individual effects. If the toxicity tests on mixtures of pharmaceuticals prove that there 
is a synergistic effect, we could have a potentiated toxic effect with severe 
consequences for the organisms in the environment that is why these studies should 
be taken into account by international laws and regulations combining them to the 
classic studies on individual substances. 
In order to address the effect of a toxic mixture several theoretical models have been 
developed, which compare toxic effects from the mixtures with a reference model in 
which it is assumed that there are no interactions between chemicals in expected 
combined effects. Two different reference models are well established: concentration 
addition (CA) and independent action (IA), both are used to describe the joint toxicity 
depending on the mode of action (MoA) of the single chemicals.  
Concentration Addition (Loewe and Muischnek, 1926) is based on the assumption 
that the mixture components have the same mechanism of action, in other words 
they act on the same biochemical pathway and strictly affect the same molecular 
target (Martin et al., 2009). This model has concentration-based summation of toxicity 
of similarly acting chemicals, scaled to reflect their relative toxicities (Loureiro et al., 
2010).  On the other hand the model of Indipendent Action, also known as Bliss 
independence, is based on the assumption that the components in a mixture of 
chemicals or in a combination of a natural and a chemical stressor do not interact 
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physically, chemically or biologically (Bliss, 1939). The IA model is, therefore, a 
measure of the joint probability of individual sensitivity to the compounds in the 
mixture assuming that the chemical mechanisms of action in fully independent 
(Martin et al., 2009).  
Chou (2006) explains that “because of biological systems as well as dose-effect 
models are exceedingly complex, there have been numerous models, approaches, 
hypotheses, and theories as well as controversies on drug combination analysis”… 
“There are many common errors associated with these claims: for instance, additive 
effect is not a simple arithmetic sum of two (or more) drugs. If A and B each inhibits 
30%, then the additive effect is not 60% because if A and B each inhibits 60%, the 
combined additive effect cannot be 120%”...“It is to be noted that in one review article 
by Goldin and Mantel (1957) alone, seven different definitions for synergism were 
given, and none of them supported the others. In a more recent review by Greco et 
al. (1995), 13 different methods for determining synergism were listed. Again, none of 
them supported the others”. Thus, pharmaceutical combination is a field of 
biomedical science rich of controversies and confusion.  
This ambiguity does not help to predict the response of organisms simultaneously 
exposed to more than one substance which remains one of the most difficult tasks in 
risk assessment. In response to the need to predict mixture effects to biota and in 
particular to aquatic environment, various models including concentration addition 
and independent action have been evaluated. Setting the combinations of 
substances concentrations to test is the first step for assessing mixture toxicity and 
interaction among chemicals; one of the most common method is using the Toxic 
Unit approach which is described in chapter 3.3.2. Another tool used for 
characterizing deviation from the reference mixture model is the MixTox model 
(Jonker et al., 2005), which is a data analyzer who consent to establish if and how 
observed data, resulting from combinations of pharmaceuticals, deviate from CA or 
IA reference model leading some interaction effect. How MixTox tool works is 
described in chapter 3.6.2. 
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1.3 Tested pharmaceuticals 
 
 
1.3.1 Fluoxetine (FLX) 
 
Fluoxetine (C17H8F3NO) is one of the most prescribed antidepressants (RxList, 2000) 
indicated for the treatment of depression, obsessive-compulsive disorder, bulimia 
nervosa, and panic disorder (Stanley et al., 2007).  
Commonly prescribed to over 40 million people globally (Eli Lilly and Co, 2001), 
fluoxetine is excreted from the human body primarirly via the urine; approximately 
2.0-11.0% of the administered dose is excreted  as unchanged parent compound 
(Altamura et al., 1994). In surface waters, Kolpin et al. (2002) reported that out of 84 
streams sampled fluoxetine concentrations did not exceed an estimated  0.012 µg/L, 
however Weston at al. (2001) indicated that fluoxetine concentrations may reach 
water concentrations as high as 0.540µg/L.  
Fluoxetine acts by blocking serotonin reuptake transporters. Physiologically serotonin 
released in the synaptic cleft is re-uptaken into the presynaptic terminal by the action 
of a specific protein pump. Fluoxetine as well as other selective serotonin re-uptake 
inhibitors (SSRI) inhibit this pump, thus increasing the serotonin level in the synapse 
space (Fent at al., 2006). Serotonin is involved in several mechanisms, hormonal and 
neuronal, and it is also important in functions such as food intake and sexual 
behavior. In invertebrate, serotonin may stimulate juvenile hormone responsible for 
controlling oogenesis and vitellogenesis (Nation, 2002). Fluoxetine, putatively by 
increasing the serotonin levels, is also known to increase reproduction in Daphnia 
(Flaherty and Dodson, 2005) at low concentration. 
 
 
1.3.2 Propranolol (PRP) 
 
Propranolol (C16H21NO2) is a non selective antagonist blocking both β adrenergic 
receptors of all subtypes. The β-1 receptors are localized in the cardiac tissue. The β-
2 are present mainly at the level of cells smooth muscle of peripheral vessels (where 
they play the role of vasodilators) and bronchi, but also in other types of tissues such 
as the heart. Overall, the stimulation of both receptors leads to an increase of cardiac 
contractility. The β-1 receptors are predominantly localized in the synaptic junction, 
while the β-2 receptors are also present at the presynaptic level, where they facilitate 
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the release of norepinephrine. The β-1 are stimulated for the more by the 
neurotransmitter norepinephrine, for which possess high affinity while β-2 are mainly 
activated by adrenaline in free circulation, which still retains an affinity equivalent to 
both receptors (Spoladore et al., 2010). The heart contains β adrenergic receptors 
(predominantly β1 receptors), which, upon agonist binding cause an increase in heart 
rate and heart contractility (positive chronotropic and inotropic responses) (Huggett et 
al., 2002). Viceversa, β-blockers inhibit the action of the endogenous catecholamines 
epinephrine and norepinephrine, reducing frequency rate and myocardial contractility 
strength. 
Besides its action as β-receptor blocker, propanolol also acts as a serotonin (5-HT) 
receptor antagonist, with affinity for the 5-HT1 receptor (Alexander and Wood 1987).  
DL-propranolol is widely prescripted for treatment of cardiovascular diseases and 
also is also used as a migraine prophylactic and to control symptoms of anxiety 
(Stanley et al., 2006). In patients with hypertension and angina, a decrease in heart 
rate and contractility is therapeutically beneficial (Huggett et al., 2002), it is also 
prescribed to treat patients after heart attack to prevent further attacks. 
β-blockers are one class of environmental pharmaceuticals that has received recent 
attention because have been detected in effluent discharges worldwide. Ternes 
(1998) reported the same maximum concetration of propranolol, with level between 
0.29 and 0.59 µg/L in effluent of sewage treatment plants as well as in rivers. 
 
 
1.3.3 Carbamazepine (CBZ) 
 
Carbamazepine (C15H12N2O) is an anticonvulsant and mood stabilizing drug used 
primarily in the treatment of epilepsy, bipolar disorder, and trigeminal neuralgia 
(Garcia-Morales et al., 2007). This antiepileptic drug is among the pharmaceuticals 
most frequently encountered in surface waters (Daughton and Ternes, 1999). 
Reports indicate that approximately 3% of the therapeutic dose is excreted 
unchanged through urine and is persistent when released to the environment, its 
average removal efficiencies by wastewater treatment plants are below 10% (Zhang 
et al., 2008). No biodegradation of CBZ even at low concentrations has been found. 
For these properties, carbamazepine is considered a marker for urban discharges. 
Fent et al. (2006) reported values in the range of 0.1-1 µg/L for surface waters, with 
levels up to 1.1 and 0.03 µg/L in groundwater and drinking waters, respectively. 
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1.3.4 Mode of action of fluoxetine and propranolol referred to Daphnia 
magna 
 
The mode of action of a pharmaceutical is evaluated for the treatment of human 
diseases, however, this desired property in a patient, might possibly provide an 
unwanted adverse effect in a non-target aquatic species (Lange and Dietrich, 2002). 
Furthermore, since in the environment  pharmaceuticals are found in mixture with 
others, we should consider  the interaction effects between substances in order to 
correctly estimate the risk posed to the aquatic organisms by pharmaceuticals. 
The two pharmaceuticals used to a larger extent in this study are propranolol and 
fluoxetine and we need to know their mode of action to understand how they could 
possibly act on Daphnia and better explain their interaction in binary mixture.  
Both of these pharmaceuticals have an effect on the action of serotonin, although 
with different mechanisms.  
Based on biochemical and pharmacological criteria, serotonin receptors are classified 
into seven main receptor subtypes, 5-HT1–7. Of major pharmacotherapeutic 
importance are those designated 5-HT1, 5-HT2, 5-HT4, and 5-HT7, all of which are 
G-protein-coupled. 5-HT1 receptors are subdivided into 5-HT1A, 5-HT1B, and 5-
HT1D receptors; while 5-HT2 subtypes include 5-HT2A, 5-HT2B, and 5-HT2C. 
With the exception of the 5-HT3 receptor, a ligand-gated ion channel, all other 
serotonin receptors are G protein-coupled receptors that activate an intracellular 
second messenger cascade to produce an excitatory or inhibitory response. 5-HT1 
receptor is coupled to the inhibition of cAMP signaling cascade in vertebrates; on the 
other hand, β-receptors are coupled to the enhancement of cAMP concentration. 
Franzellitti et al. (2010) found that propranolol increased cAMP levels in the 
mantle/gonads of the mussel, Mytilus galloprovincialis, possibly by blocking 5HT1 
receptors thus reducing the effects of physiological inhibitors of the cAMP pathway, 
such as serotonin. 
Cyclic adenosine monophosphate (cAMP, cyclic AMP or 3'-5'-cyclic adenosine 
monophosphate) is a second messenger important in many biological processes as 
intracellular signal transduction, transferring into cells the effects of hormones like 
glucagon and adrenaline, which cannot pass through the cell membrane; it is also 
involved in the activation of protein kinase A (PKA) which is normally inactive. A 
protein kinase is a kinase enzyme that modifies other proteins by chemically adding 
phosphate groups to them (phosphorylation). Phosphorylation usually results in a 
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functional change of the target protein (substrate) by changing enzyme activity, 
cellular location, or association with other proteins. Kinases are known to regulate the 
majority of cellular pathways, especially those involved in signal transduction. cAMP 
is synthesised from adenosine triphosphate (ATP) by adenylyl cyclase (AC) located 
on the inner side of the plasma membrane. Adenylyl cyclase is activated by a range 
of signaling molecules through the activation of adenylyl cyclase stimulatory G (Gs)-
protein coupled receptors and inhibited by agonists of adenylyl cyclase inhibitory G 
(Gi)-protein-coupled receptors.  
For our research it is interesting to understand how the previously described 
physiological mechanisms work in the crustacean Daphnia magna. 
The mechanisms of action of SSRIs affecting phenotypic responses of exposed D. 
magna were analyzed by studying effects on level of lipids, carbohydrate, proteins, 
oxygen consumption rates, survival, and offspring production (Campos et al., 2012). 
The results from this study showed that SSRIs act following a mechanism of action 
similar or identical to their intended pharmacological effects in humans by increasing 
serotoninergic  activity, but in doing so they alter physiological process as increasing 
glycogen and aerobic metabolism. Furthermore, the recent sequencing and public 
deposition of the genome of Daphnia pulex provide an alternative approach to protein 
discovery in crustaceans. Despite the genome of its close relative Daphnia magna is 
still incomplete, we may benefit from the former. McCoole et al. (2012) using D. pulex 
genomic information and Drosophila melanogaster proteins as queries (in D. 
melanogaster  three serotonin receptors subgroups has been identified and 
characterized: 5HT1R, 5HT2R and 5HT7R, which are the homologs of those present 
in the human) identified putative serotonin receptor subgroups in Daphnia pulex: type 
1 (5HT1R) and the type 7 (5HT7R). No Daphnia 5HT2R homologs were identified. 
As regards the presence of the adrenergic receptors (α, β) in Daphnia magna, 
Huggett et al. (2002) referred that the presence have never been reported in 
crustaceans; however  in genomic studies on Daphnia pulex, McCoole et al. (2012), 
on the basis of D. melanogaster sequences, identified D. pulex genes encoding 
putative members of the OctαR and OctβR octopamine receptors classes. 
Octopamine is the crustacean adrenergic agonist equivalent to dopamine in 
vertebrate, and its receptors are similar to adrenergic receptors (Dzialowski et al., 
2006). 
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1.4 Daphnia magna Straus, 1820 
 
 
1.4.1 Daphnia magna phylogeny and characteristics 
 
Table 1.1. Scientific classifcation of Daphnia magna 
Kingdom Animalia 
Phylum Arthropoda 
Subphylum Crustacea 
Class Brachiopoda 
Order Cladocera 
Family Daphniidae 
Genus Daphnia 
Species magna 
 
The gender Daphnia was given its name by O.F. Mueller in 1785, but it had been 
known to scientists for more than a century before that (Edmonson, 1987). 
Swammerdam (1669) used the term water flea, a term taken up in 1675 by his 
acquaintance Leeuwenhoek (Dobell 1932).  
The planktonic species Daphnia magna belongs to the phylum Arthropoda (Table 
1.1) and shares with all other members of this phylum an exoskeleton, jointed limbs 
and a hemocoel as primary internal cavity. The hemocoel accommodates their 
internal organs and has an open circulatory blood or hemolymph system (Ruppert et 
al., 2004).  
The exoskeleton forces members of the phylum Arthropoda to moult, shedding the 
old exoskeleton in favor of a new one, in order to grow (Ruppert et al., 2004). D. 
magna belongs to the subphylum Crustacea. Crustaceans main differences to other 
Arthropods are the presence of a nauplius larva, although often suppressed in favor 
of a more advanced larva at the hatching stage (Ruppert et al., 2004), and biramous 
(splitted) limbs (Hejnol and Scholtz, 2004). Daphnia belongs to the class 
Branchiopoda and to the subclass Cladocera with whom it shares a two-valved 
carapace covering most of the body except the antennae. All Cladocerans have an 
unpaired compound eye which is the result of a fusion of two eyes in the late 
embryonic development (Ebert, 2005). An also unpaired nauplius eye is located 
between the compound eye and the mouth (Fig. 1.3).   
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Fig. 1.3. The functional anatomy of Daphnia (source: 
http://www.evolution.unibas.ch/ebert/publications/parasitismdaphnia/ch2f1.htm) 
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Like other Crustaceans, D. magna has two pairs of antennae. The first pair of 
antennae is located beneath the rostrum and acts as a sensory organ (Ebert, 2005). 
In female D. magna the first pair of antennae is rudimentary and does not protrude 
over the rostrum, in male D. magna, however it is elongated and movable (Mitchell, 
2001). The second pair of antennae is used for locomotion. 
The average number of eggs per instar is approximately six to ten. 
D. magna plays a very important ecological role in freshwater habitats, this includes a 
role as a very efficient filter feeder, in fact Daphnia magna has been classified as fine 
mesh filter feeders (Geller and Muller, 1981), being able to filter particles suspended 
in the water column with a minimum size as small as 200 nm. This capacity makes 
Daphnia sensitive to environmental conditions and to a whole range of contaminants, 
in addition to a short life cycle observable in laboratory, it is not surprising that 
several studies have focused on D. magna as test species when assessing the 
effects of compounds in the aquatic environment as explained in sections 1.4.3 and 
1.4.4. 
 
 
1.4.2 Life cycle 
 
Under ideal environmental conditions D. magna reproduce parthenogenetically 
producing clonal offspring. Development of eggs is direct (immediate). At 20ºC, the 
embryos hatch from the eggs after about 1 day but remain in the brood chamber for 
further development. After about 3 days in the brood chamber, the young Daphnia 
are released by the mother through ventral flexion of the post-abdomen. The 
newborn look more or less like the adult Daphnia, except that the brood chamber is 
not yet developed (Ebert, 2005). Usually, only females develop from the 
parthenogenetic eggs, but under certain environmental conditions which can be 
stressful conditions, as a change in e.g. temperature or food levels, males can also 
born with subsequent sexual reproduction. Fertilized, amphigonic eggs are extruded 
into the brood chamber which is modified to form the ephippium. The development of 
these eggs is arrested early and the ephippium, containing the dormant embryos, is 
shed at the maternal molt (Zaffagnini, 1987). After a resting period, only females 
develop from amphigonic eggs. The two sexual and asexual cycles are illustrated in 
Fig. 1.4.  
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Males should not be present in a laboratory culture reared under a regime of constant 
light, temperature and food. At 20ºC D. magna reach sexual maturity in 6 - 8 days 
releasing their eggs into a brood chamber. The embryos complete their development 
inside the brood chamber and hatch as free – swimming neonates at day 8 - 10. In 
the following 2 - 4 days the mature females release a 2nd brood of neonates with 
reproduction peaking around the 3rd brood (day 12 -14) or 4th brood (day 14 - 17). As 
the adults become older the time between broods will increase and the size of the 
brood will decrease.   
D. magna has three to five juvenile instars (developmental stage between moults), 
followed by a single adolescent instar and 6-22 adult instars. Each instar is 
terminated by a molt. Under favorable conditions an instar lasts two days but can last 
up to a week under unfavorable conditions. The average number of eggs per instar is 
approximately six to ten. 
The life span of a single D. magna depends on environmental conditions like 
temperature or food supply and is roughly 40 days at 25°C, and about 56 days at 
20°C (U.S. EPA, 2002).  
 
 
Fig. 1.4. Sexual and the asexual (parthenogenetic) life cycle of a 
Daphnia. Drawing by Dita B. Vizoso, Fribourg University 
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1.4.3 Daphnia as a model organism 
 
 
 
 
 
 
The crustaceans of the genus Daphnia (Fig. 1.5), have been subject to intense 
biological investigations for over a century. Daphnia species have a rich literature and 
are sensitive test organisms which respond to environmental stressors that are 
important factors affecting freshwater ecosystems integrity. Daphnia is increasingly 
used as a model organism, extensively studied to understand particular biological 
phenomena, it is highly sensitive to pollution and it is used for evaluating 
environmental toxicity of chemicals on aquatic invertebrates. The characteristics that 
make Daphnia a model organism for ecotoxicological laboratory studies are: 
 relatively easy to grow and maintain in a restricted space; 
 relatively easy to provide necessary nutrients for growth; 
 parthenogenetic mode of reproduction and short life cycle (egg to adult in less 
than 10 days); 
 relatively well understood growth and development; 
Moreover, Daphnia species, as a whole, have a wide, nearly cosmopolitan, 
distribution.  They occur in a highly diverse set of habitats ranging from freshwater to 
lakes. 
 
 
 
 
 
 
Fig. 1.5. A Daphnia magna specimen coming from 
laboratory cultures at CIRSA 
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1.4.4 Use of Daphnia magna in aquatic toxicity tests 
 
A toxicity test, also referred to as bioassay, is an experimental determination of the 
effects of a material on a selected group of organisms under defined conditions. An 
environmental toxicity test measures effect after exposure to specific concentrations 
of chemical, effluent, elutriate, receiving water, sediment or soil. 
Current risk assessment methodologies require the deployment of standard assays 
and species for the detection of hazard in relation to specific scenarios (U.S. EPA, 
2002). Multiple methods have been standardized by multiple organizations, e.g.: 
 American Society for Testing and Materials (ASTM); 
 Organization for Economic Cooperation and Materials (OECD); 
 International Organization for Standardization (ISO); 
 National Toxicology Program (NTP). 
 
This approach brings many advantages: 
 Test are uniform and comparable to previous results within the same or other 
laboratories; 
 Can be replicated (confirmed) by other laboratories; 
 Makes it easier for decision makers to accept test results; 
 Logistics are simplified, developmental work already done; 
 Methods establish baseline from which modifications can be made if 
necessary; 
 Data generated can be combined with those from other laboratories for use in 
ERA’s; 
 Detailed listing of apparatus, dilution water, test material, test organisms, etc; 
 Experimental, analytical and documentation procedures are detailed. 
 
But there are also some disadvantages: 
 Often very specific and, as such, hard to apply to other situations or answer 
other questions; 
 Tend to be used in inappropriate situations; 
 May not be applicable to natural environment. 
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Several standard methods have been developed for a range of test species 
(cladocerans, freshwater fishes, insects, oligochaete, marine and freshwater 
amphipods and green algae) depending on their life cycle and habitat, for different 
types of toxicity test. There are different protocols for testing pollutants in the water 
column and attached to the sediment, for freshwater as well as for saltwater. 
Standard aquatic toxicity tests can be divided into: acute and chronic tests.  
 
 Acute tests are short term tests and mostly have mortality as the endpoint. 
They can be divided into static, non renewable tests, static renewable and flow 
through tests. The Daphnia acute test is a static non-renewable tests, which is 
the simplest one; the tests water is not renewed over the test period. They are 
very cost effective, but are the least realistic and sensitive tests. 
 Chronic tests simulate several, or a continuous, application and cover a 
substantial part of the organisms’ life cycle. They can have different endpoints 
that are affected by sublethal concentrations of the contaminant. The most 
accurate method to ensure that the concentration of a pollutant, or effluent, is 
kept at the required level is the flow-through method. Here the test chambers 
are provided continuously with the solution or suspension to be tested to keep 
the concentrations stable. The downside of the flow-through method is that it is 
very labor intensive and requires large amounts of test solution. The Daphnia 
chronic test is a static renewal test where organisms are fed during the all test 
to keep them alive and able to reproduce. Test organisms are exposed to a 
fresh solution of the same concentration of test sample at a defined time 
interval, either by transferring the test organisms from one test chamber to 
another, or by replacing all or a portion of solution in the test chambers. The 
risk of volatilization and degradation is reduced in this method but it is still 
existent. The renewal method provides an acceptable tradeoff between labor 
intensity, feasibility in laboratory work and simulating possible natural 
occurrences.  
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1.5 Selected battery of biomarkers 
 
Utility of biochemical approaches in environmental pollution monitoring is based on 
the assumption that low concentration of a toxicant will cause biochemical responses 
within individual organisms before these effect are observed at higher levels of 
biological organization (Sarkar et al., 2006).  
The EU Water Framework Directive (WFD, Directive 2000/60/EC), requiring to 
assess the achievement of good chemical and ecological status of water bodies, 
pointed out the importance of biological monitoring for the determination of water 
quality. Biomarkers, although not incorporated in the WFD, are among the emerging 
biological monitoring tools considered for use in monitoring programs necessary for 
the implementation of the WFD. Allan et al. (2006) proposed the use of biomarkers in 
the WFD in order to “provide more realistic assessment of impacts and exposure of 
aquatic organisms to specific contaminants present in water”. 
When a toxic compound penetrates into an ecosystem, it can cause a variety of 
damages at different levels of hierarchical organization, from the primary level of 
toxicity at the molecular level, determining changes in enzyme activities, alterations in 
DNA, to the higher levels of biological organization as cells, tissues, organs and 
organisms until it reaches the levels of populations and communities. Biomarkers are 
indices of stress, they can be defined as cellular, biochemical or molecular alterations 
which can be detected and quantified in a tissue or cell of an organism exposed to a 
contaminant before the effect is observed on the survival or reproduction of the 
organism itself. In particular, the responses at the primary level often represent 
cytoprotective responses since they tend to decrease the toxic effect of the pollutant 
through the activation of multienzymatic systems. These enzymatic systems can 
detoxify all or part of the body.  
One of the early biomarkers characterizing the environmental exposure is 
represented by the inhibition of the enzyme acetylcholinesterase (AChE), biomarker 
indicating effects on nervous system.  
Other biomarkers assess which level of oxidative stress is reached by the organism. 
Oxidative stress is caused by an imbalance between the production of highly reactive 
chemical species, free radicals, and the physiological defense capabilities, 
antioxidants. The cellular damage can begin at the level of the lipid membrane (and 
malondialdehyde is an intermediate product of lipid peroxidation) until to DNA 
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damages. Reactive oxygen species (ROS) play a key role in mediating of 
cellular/tissue damage because the oxygen, in addition to being essential to life, it is 
also toxic. Among the most important ROS there are: 
 HO• hydroxyl radical; 
 • 2O  superoxide anion; 
 H2O2 hydrogen peroxide; 
 O2 singlet oxygen. 
The free radical produced in higher quantities is the superoxide anion • 2O . It reacts 
with the hydrogen peroxide H2O2 and form the dangerous hydroxyl radical HO•. 
Organisms are equipped to defend themselves from the presence of these free 
radicals with molecules anti-radicals, which belong to antioxidant system..  
Antioxidants can be divided into enzymatic and non-enzymatic subtypes. Several 
antioxidant enzymes are produced by the body, with the three major classes being 
the superoxide dismutase (SOD), which converts superoxide anion into hydrogen 
peroxide, catalase (CAT), which metabolizes H2O2 to molecular oxygen and water 
and the reduced glutathione (GSH) peroxidases which is described in paragraph 
2.4.3. Non-enzymatic antioxidants include vitamins obtained through the diet, such as 
α-tocopherol (vitamin E), ascorbic acid (vitamin C), and β-carotene.  
If, however, the quantity of free radicals produced is higher than the physiological 
response and the antioxidant system is not able to neutralize this excess, free 
radicals will cause damages. As an overall, this phenomenon is called oxidative 
stress. 
Daphnia magna is widely used as test organism in acute 48-h inhibition and chronic 
21-d reproduction tests in the aquatic toxicology field., but also a number of 
biochemical biomarkers have been studied in Daphnia magna for assessing the 
potential impact of chemicals on the aquatic environment. Most biomarkers have 
been evaluated on Daphnia after acute exposure to pesticides or metals, only few 
studies have been conducted on pharmaceuticals after a chronic or sub-chronic 
exposition.  
The use of biomarkers does not give a quantitative assessment of the toxicity level in 
a organism, but determinates its “state of health" from the state of homeostasis to 
that of disease, and can predict the "level of risk" to which the organism is subjected. 
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1.5.1 Acetylcholinesterase (AChE) 
 
AChE activity serves to terminate synaptic transmission, preventing continuous nerve 
firings at nerve endings. Therefore, it is essential for the normal functioning of the 
central and peripheral nervous system. AChE hydrolyzes acetylcholine into choline 
and acetate after activation of acetylcholine receptors at the postsynaptic membrane. 
Inhibition of AChE provokes an absence of such hydrolysis resulting in 
overaccumulation of acetylcholine and prolonged electrical activity at nerve endings 
occurs. The inhibition of AChE is usually an indicator of exposure to 
organophosphates and carbamates pesticides, but also metals can affect this 
enzyme. 
 
 
1.5.2 Malondialdehyde (MDA) 
 
Polyunsaturated fatty acids, contained in the membranes, are particularly susceptible 
to attack by free radicals. The removal of a hydrogen atom by a -CH2- group from a 
radical (usually HO•) leads to the formation of a lipid radical, which may react with 
oxygen to give a radical perossilipidic (LOO•). This can extract a hydrogen atom from 
a chain of fatty acids adjacent and initiate a cascade of reactions, which convert other 
membrane lipids in lipid hydroperoxides (L- OOH). 
LH + R• → L• 
L• + O2 → LOO• 
LOO• + LH → L• + LOOH 
This process is called lipid peroxidation and is a major cause of the loss of cell 
function under conditions of oxidative stress. Indeed, the presence of L- OOH in a 
membrane can compromise its functionality by altering the fluidity and allowing ions 
to freely pass through. This can result also in a rupture of the membrane itself. This 
process of deterioration O2-dependent which leads to an alteration of the integrity of 
biological membranes, has as product the lipid peroxides and their by-products such 
as aldehydes. Among these, the malondialdehyde (MDA) is the main product of the 
lipidic peroxidation. 
MDA assess is used as a non-enzimatic marker of oxidation of phospholipidic 
membrane and an increment in MDA level in organisms it has been considered a 
relevant index of chemical damage induced by toxicants. 
35 
 
1.5.3 Glutathion S-trasferase (GST) 
 
The antioxidants include glutathione (GSH) which is a tripeptide extremely important 
for the health of the cell and performs several functions: it is the substrate of some 
antioxidant enzymes, plays an action against scavenger of hydroxyl radicals and 
singlet oxygen, and also has a role in the regeneration of vitamin E (Reddy et al., 
1983). The defense system has evolved a battery of enzymes to combat the 
formation of oxygen radicals, GST belongs to the class of phase II detoxifying 
enzymes that catalyse the conjugation of glutathione with xenobiotics, including 
organophosphates. Induction of GST activity is an indication of a detoxification 
process. GST also catalyses the conjugation of glutathione with cytotoxic aldehydes 
produced during lipid peroxidation (Halliwell and Gutteridge, 1999). The activity of 
antioxidant enzymes is potentially a useful biomarker in the assessment of the quality 
of aquatic environments.  
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2. Aim of the work 
 
The increased pharmaceuticals consumption together with the recent development of 
more sensitive analytical techniques has lead to identification of pharmaceuticals as 
emerging contaminants in the aquatic environment (Quinn et al., 2008). As 
pharmaceuticals are continuously added and not efficiently removed by wastewater 
treatment plants, certain pharmaceuticals exhibit pseudopersistence, giving rise to 
concerns for the health of aquatic wildlife and a theoretical risk to humans who 
consume these organisms or drink the water in which they live (Franzellitti et al., 
2011). Pharmaceuticals are present in surface waters at low concentrations of ng-
μg/L, and standard acute ecotoxicity data reported for a number of pharmaceuticals 
may not be sensitive enough to adeguately characterize the risk associated with 
these chemicals (Brooks et al., 2003). To the other hand there is very little 
information about chronic toxicity. To fill this gap of information we tested 
pharmaceuticals known to be widespread in freshwaters combining ecotoxicological 
48-h acute inhibition test with 21-d chronic reproduction tests on the crustacean 
Daphnia magna, a representative freshwater zooplankton species. 
Regulatory risk assessment of chemicals and the majority of ecotoxicological studies 
in the aquatic and terrestrial environments focus mainly on the toxicity of single 
compounds (Barata et al., 2006). However, organisms in the environment are 
constantly exposed to complex mixtures or combination of stressors (Pavlaki et al., 
2011). Since a chemical will be rarely found alone in the environment but commonly 
in combination with others (Pavlaki et al, 2011) a further aim of this work was to 
understand the ecotoxicological effect of the binary mixtures of the pharmaceuticals 
propranolol and fluoxetine. Since the possible antagonistic or synergistic interactions 
that can occur between chemicals (Loureiro et al., 2010) makes difficult the 
assessment of environmental hazards of complex mixtures to evaluate the possible 
interaction effects between pharmaceuticals we used the MixTox model (Jonker et 
al., 2005), a data analysis tool used in the ecological risk assessment to predict 
mixture effects from concentrations of the component substances. The MixTox tool 
highlights a possible antagonistic or synergistic effect between chemicals and 
indicates if this effect depends upon the composition or the concentration of the 
compounds in the mixture. 
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The research has been completed assessing the response of Daphnia magna to 
fluoxetine at the physiological level: production of malondialdehyde, and 
acetylcholinesterase and glutathione s-transferase enzymatic activities were 
measured.  
The study intends to bring new knowledge on evaluation of toxicity of pharmaceutical 
residuals in the environment, and provide a useful method to be applied in the 
ecological risk assessment.   
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3. Materials and methods 
 
3.1 Culturing of Daphnia magna 
 
Daphnia magna has been successfully cultured in the Laboratory of Ecotoxicology of 
CIRSA for more than ten years. Cultures of D. magna were maintained in 8 L 
capacity plastic vessels (Fig. 3.1), and were fed three times a week with a mixture of 
around 108 cells of the green alga Pseudokirchneriella subcapitata (for counting see 
paragraph 3.4) and 40 mg of brewer’s yeast. The cultures were kept in a controlled 
temperature chamber at 20°C at 16:8 light:dark photoperiod through neon tubes and 
culture medium was renewed once a week. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This allowed to maintain the Daphnia cultures in good conditions ready to be used for 
the tests. Periodically organisms condition were checked by a 24-h acute 
immobilization test in according with ISO (1996) with potassium dichromate (K2Cr2O7 
CAS number 7778-50-9) in order to evaluate if the sensitivity of Daphnia was in the 
range expected from the guideline.  
 
 
 
Fig. 3.1.  Daphnia cultures maintained in 8 liter plastic vessels at 
constant environmental conditions 
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3.1.1 Daphnia Medium 
 
Two different kinds of water were used as culture and test medium, both maintained 
and aerated in 20 L tanks (Fig. 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Acute and sub-chronic test medium (hereafter ISO water)  was made in 
accordance with ISO (1996) protocol. Before starting the test the water was 
oxygenated for 24 h. After aeration The water had a pH of 7.8 ± 0.2, a 
hardness of 250 mg/l ± 25 mg/l (expressed as CaCO3), a molar Ca/Mg ratio 
close to 4:1 and a dissolved oxygen concentration above 7 mg/l. This medium 
was prepared by mixing 250 ml of each of the four solutions reported below 
and by bringing the total volume to 10 liters with distilled water. The four 
solutions were made by dissolving four salts in distilled water:  
 
 
Fig. 3.2. Two 20 liters tanks containing the re-constituted water 
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1) Calcium chloride solution: 11.76 g/L of calcium chloride dihydrate 
(CaCl2.2H2O); 
2) Magnesium sulfate solution: 4.93 g/L of magnesium sulfate heptahydrat 
(MgSO4.7H2O); 
3) Sodium bicarbonate solution: 2.59 g/L of sodium bicarbonate (NaHCO3); 
4) Potassium chloride solution: 0.23 g/L of potassium chloride (KCI); 
     
    Due to the paucity of salts in the ISO water, this kind of water has not    
    been used to maintain Daphnia cultures or for the reproduction test. 
 
 The culture and chronic test medium (hereafter culture water) was made by 
mixing in the same proprortion the ISO water and a natural spring water, 
commercialized as bottled mineral water (Acqua Guizza, Acqua minerale San 
Benedetto S.p.A., Scorzè, Italia). The choice of the Guizza (was determined 
by its salt composition (Table 3.1), in fact the sum of the salts which compose 
the two waters is very close to the salt concentration required by the chronic 
test protocol ISO 10706:2000 annex B (ASTM water). The only big difference 
between our culture water and water required by the protocol is for the paucity 
of sulphates in our culture water respect to ASTM water.  
 
                  Table 3.1 Composition of Guizza and the ISO water 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 Water composition 
 Mg
++ 
NO
3+ 
SO4
-- 
K+ Ca
2+ 
SiO2 Na+ Cl- F- 
Guizza (mg/L) 28.7 8.7 4.0 1.1 49.0 17.5 6.5 2.4 <0.15 
ISO 6342 (mg/L) 12.0  0.05 3.0 80.5  17.7 0.003  
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3.1.2 Algae culturing 
 
The green algae have been cultured in 1 liter flasks (Fig. 3.3) under non-aseptic, but 
controlled conditions of temperature (20°C), photoperiod (16:8 light:dark) and 
aeration. Each culture was grown from a 10 ml inoculum derived from an older 
culture. The culture medium was in accordance with Gorbi (1987) and was composed 
by 8 solutions dissolved in distilled water. A concentrated medium was prepared by 
mixing 20 ml of solutions 1 to 7 and 2 ml of solution 8, and then bringing the volume 
to 1liter with distilled water. This concentrated medium was diluted tenfold with 
distilled water to obtain the culture medium.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3. Flask of algal culture maintained under controlled conditions. 
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The salts solutions are: 
 
1. 2.55 g NaNO3 in 100 ml distilled water  
2. 0.104 g K2PO4 in 100 ml distilled water 
3. 1.22 g MgCl26H2O in 100 ml distilled water 
4. 1.47 g MgSO47H2O in 100 ml distilled water  
5. 0.441 g CaCl2*2H2O in 100 ml distilled water  
6. 1.50 g NaHCO3 100 ml distilled water  
7. Fe EDTA (0.096 g FeCl3 + 0.300 g Na EDTA 2H2O in 1 liter distilled water) 
8. 10 ml 8A solution (0,0327 g/l ZnCl*6H2O), 1 ml 8B solution (0,0726 g/l 
NaMoO4 2H2O), 1 ml 8C solution (0.0143 g/l CoCl2 6H2 O), 0,1 ml 8D solution 
(0.141 g/l CuCl2*2H2O), 0.186 g H3BO4, 0.416 g MnCl2*4H2O, diluited to 1 liter 
distilled water 
 
The normal growth period of Pseudokirchneriella subcapitata cultures was about 6 
days. At the end of the growth period the algae culture was sedimented in a beaker 
for about a week and then resuspended in culture water.  
During the reproduction tests, algae were often controlled under microscope to make 
sure that within the culture there was always just the type of algae indicated in the 
protocol. 
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3.2 Tested substances 
 
3.2.1 Fluoxetine 
 
 
 
 
 
 
 
 
 
 
 
 
Fluoxetine, currently marketed as fluoxetine  hydrochloride, is a chiral molecule (Fig. 
3.4). In the present study the racemic mixture of fluoxetine hydrochloride 
((±)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine hydrochloride), 
CAS number 56296-78-7,  which contains equal parts of the  two enantiomers R- and 
S- has been used. The substance was purchased from Sigma Aldrich (Milan, Italy). 
FLX hydrochloride is readily soluble, so no solvents were necessary for preparation 
of stock solutions, which were therefore prepared in ISO or culture water for 
acute/sub-chronic and chronic test exposure respectively. Nominal concentrations 
were not analytically verified for this study. 
 
3.2.2 Propranolol 
 
 
 
 
 
 
Fig. 3.4. Structure and configuration of fluxetine hydrochloride 
used for testing. 
Fig. 3.5. DL-Propranolol hydrochloride used for testing 
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Propranolol, commercially available as propranolol hydrochloride, is a chiral molecule 
(Fig. 3.5) which exists in the form of two enantiomers with different spatial 
configuration: (S) - (-) - propranolol and (R) - (+) – propranolol. In this study we used 
the racemic mixture DL-Propranolol hydrochloride ((±)-1-Isopropylamino-3-(1-
naphthyloxy)-2-propanol hydrochloride), CAS number 318-98-9. The substance was 
purchased from Sigma Aldrich (Milan, Italy). PRP hydrochloride is readily soluble, so 
no solvents were necessary for preparation of stock solutions, which were therefore 
prepared in ISO or Culture water for acute/sub-chronic and chronic test exposure 
respectively. Nominal concentrations were not analytically verified for this study.  
 
3.2.3 Carbamazepine 
 
 
 
 
 
 
 
Carbamazepine (Fig. 3.6) (5H-Dibenz[b,f]azepine-5-carboxamide), CAS number  
298-46-4, was purchased by Sigma (Milan, Italy). Due to its low solubility it was not 
possible to dissolve CBZ in water; for this reason a stock solution was prepared 
dissolving CBZ in ethanol. This solution was further diluted with ISO water in order to 
reach in the highest CBZ concentration an ethanol concentration of 1% (v/v) in order 
to avoid a toxic effect due to this solvent. 
 
 
Fig. 3.6. Structure of Carbamazepine 
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3.3 Acute Immobilization Toxicity Test 
 
All acute experiments were conducted in accordance with the ISO 6341 standard and 
the OECD 202 guideline. The same procedure was used for both single chemical and 
mixture exposures, only the experimental designs were different. 
One day before the start of the exposure to the chemicals, adult females containing 
parthenogenetic eggs (no first brood progeny) were isolated by eliminating the 
juveniles from the culture vessels and then kept under the same culture conditions. 
They derived from healthy stocks with no signs of stress such as high mortality, 
presence of male or ephippia. The next day, newborns (less than 24 h old) present in 
the culture vessels were collected and exposed to different concentrations of 
pharmaceuticals. Groups of five daphnids for beaker were placed in a 25ml glass jar 
containing 20ml of test solution. The acute test involves at least five concentrations 
arranged in a geometric series with a separation factor not greater than 2.2, of which 
the highest concentration must determine the 100 % of immobilization and the lowest 
no observable effect. Test solutions of the chosen concentrations are prepared by 
dilution with ISO water of a stock solution prepared before. Beakers were randomly 
placed into trays at the same condition of light and temperature of the cultures. 
Daphnids were not fed during the test. After 24 and 48 h daphnids were observed 
and the number of mobile individuals in each container was reported. Those which 
were not able to swim after gentle agitation of the liquid for 15 s have been 
considered immobilized. Results of experiments were considered as valid if the 
percentage immobilization of the controls was less than or equal to 10 %.  
 
 
 
3.3.1 Acute test on reference toxicant (potassium dichromate) 
 
The acute test with potassium dichromate (K2Cr2O7) has been carried out 
periodically, with the aim to verify that the sensitivity of Daphnia magna were 
maintained within a range of acceptable variability. Seven increasing concentrations 
were prepared, with two replicates per concentration, in a geometric series from 0.80 
to 3.00 mg/L (0.80, 1.00, 1.24, 1.55, 1.93, 2.41, 3.00 mg/L) of potassium dichromate 
obtained by diluting a stock solution of 100 mg/L and a control treatment with water 
as only dilution. After 24 hours from the beginning of the test in each beaker the 
number of individuals still alive was counted and were reported. 
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3.3.2 Acute single pharmaceuticals exposure 
 
Preliminary tests were performed in order to determinate the range of concentrations 
to be tested in the final toxicity tests. For each chemical, the highest concentration 
tested in the final tests was the lowest among the concentrations that caused 100% 
immobilization in the range finding tests. The lowest concentration tested in the final 
tests was the highest among the concentrations that did not cause any observable 
effect. Within this range, seven test concentrations, arranged in a geometric series 
were used. The seven nominal concentrations were from 3 to 12 mg/L for 
propranolol, from 2 to 20 mg/L for fluoxetine and from 60 to 130 mg/L for 
carbamazepine. 
The experimental design consisted in 8 treatments (7 concentrations plus control), 
two replicate beakers for each treatment. Experiments with propranolol and fluoxetine 
have been repeated three times, with carbamazepine twice.  
 
 
3.3.3 Acute mixture pharmaceuticals exposure: Toxic Unit approach. 
 
Toxicity tests on mixtures were carried out using the same procedures as the 
respective single-compound tests, the only difference being the adoption of a fixed-
ratio ray experimental design (Meadows et al., 2002). 
Treatments consisted in a control (test medium only) and 25 mixtures of propranolol 
and fluoxetine, identified using two criteria: total concentration and proportion of the 
two chemicals in the mixture.  
Concentration of each chemical was expressed as TU50, i.e. the concentration of the 
chemical (mg/L) divided by its EC50 (the EC50 values estimated from the single 
pharmaceutical experiments were used). Total concentration of each mixture was 
computed as ∑TU50, i.e. as the sum of the TU50 of the chemicals making up the 
mixture. Five total concentrations were tested: 0.5, 0.71, 1, 1.41 and 2 ∑TU50.  
For each total concentration, five mixtures were tested that differed in the proportion 
of ∑TU50 contributed by each of the two substances: 100:0, 75:25, 50:50, 25:75 and 
0:100% (Table 3.2). The resulting treatment concentrations of propranolol and 
fluoxetine, as mg/L, were calculated using the EC50 estimated in the single chemical 
experiments (Fig. 3.7). This concentration decision system allows to have a 
standardized method since 1 TU of a substance has the same effect of 1 TU of 
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another substance (in this case the loss of 50 % of survival or reproduction of 
Daphnia). 
Two replicate beakers for treatment were used in each experiment; three 
independent experiments were carried out.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TU in the mixture 
0.50 0.71 1.00 1.41 2.00 
100 % PRP 0.50 0.71 1.00 1.41 2.00 
0 % FLX 0.00 0.00 0.00 0.00 0.00 
Tot MIX 0.50 0.71 1.00 1.41 2.00 
75 % PRP 0.38 0.53 0.75 1.06 1.50 
25 % FLX 0.13 0.18 0.25 0.35 0.50 
Tot MIX 0.50 0.71 1.00 1.41 2.00 
50 % PRP 0.25 0.35 0.50 0.71 1.00 
50% FLX 0.25 0.35 0.50 0.71 1.00 
Tot MIX 0.50 0.71 1.00 1.41 2.00 
25 % PRP 0.13 0.18 0.25 0.35 0.50 
75 % FLX 0.38 0.53 0.75 1.06 1.50 
Tot MIX 0.50 0.71 1.00 1.41 2.00 
0 % PRP 0.00 0.00 0.00 0.00 0.00 
100 % FLX 0.50 0.71 1.00 1.41 2.00 
Tot MIX 0.50 0.71 1.00 1.41 2.00 
Fig. 3.7. Fixed-ratio ray design adopted in the acute mixture 
exposure experiments. Each point indicates the propranolol and 
fluoxetine concentration (mg/L) of an actually tested mixture. 
Along each ray, the proportion of ∑TU50 contributed by each of 
the two substances is constant, while ΣTU50 increases moving 
away from the origin of the axes. 
 
Table 3.2. Concentrations assayed expressed in TU. In each column the total concentration in the mixtures is constant 
increasing from the left to the right part of the table; in the lines the percentage of the pharmaceuticals in the mixtures is 
constant (propranolol decreasing and fluoxetine increasing top-down). 
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3.4 21-d Chronic Reproduction Toxicity Test 
 
21 days Daphnia magna chronic toxicity test was carried out according to 211 OECD 
procedure and ISO 10706 standard. The same procedures were used for both single 
and mixture exposures, only the experimental designs were different. To initiate the 
test daphnids younger than 24 h were collected as described at paragraph 3.2. They 
were placed in a 100 ml glass jar containing 50 ml of test solution. One daphnid was 
deployed in  each beaker. Concentrations were made by diluition of stock solution in 
culture water (aerated for 24 h before test initiation and every medium renewal). 
Containers were marked and placed randomly under a light source and incubated at 
the same environmental condition of cultures. This was a static renewal test, which 
means that water and nutrients were renewed three times a week in order to maintain 
good conditions for daphnids which must grow up and reproduce. Every time the 
medium was renewed newborns were counted and removed from the vessels. After 
21 days we counted the number of neonates per surviving organism. In accordance 
with ISO 10706, the results of a test were considered valid when the following criteria 
were respected: 
a) the total number of control replicates exhibiting adult mortality and male 
development was ≤ 20 % at the end of the test; 
b) the mean number of living offspring per living parent in the controls was ≥  60 (the 
control animals have to produce their first brood within 11 days from the start of the 
test otherwise criterion may not be met); 
Organisms were fed with living algal cells of Pseudokirchneriella subcapitata and a 
suspension of brewer’s yeast. Diet was constant during the test, but a lower rate was 
used at the beginning and then increased during the test to take account of growth of 
the parent animals.  
A series of preliminary experiments was carried out in order to set up the method and 
to identify the feeding regimen that enabled to meet the above criteria. 
Pseudokirchneriella subcapitata cells were counted with a microscope and a  Bürker 
counting chamber (Fig. 3.8). The chamber consists of a thick glass microscope slide 
with indentation that creates a grid. The grid is divided in squares and rectangles of 
different sizes. The device is carefully crafted so that the area bounded by the lines is 
known, and the depth of the chamber is also known. This allows an easy counting of 
cells:  
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The number of cells in a specific volume of the chamber was counted, and then we 
calculated the concentration of cells in the fluid. The mean of the counting of three 
replicates was the basis for a series of dilutions to reach the required cell density in 
the test medium.  
In the final tests Daphnia magna were fed with 1.25*108 cell/l/d and 80 mg/L/d of 
brewer’s yeast. We fed only 75% of the daily dose of nutrients during the first week. 
The total organic carbon amount of the food ration was assessed combining dry 
weight and CHN analysis data from algal cells and brewer’s yeast. The total organic 
carbon feeding amount was 0.123 mg per animal per day, within the interval 
prescribed by ISO 10706 (0.1 to 0.2 mg of carbon per animal per day).  
 
 
 
Fig. 3.8. Bürker chamber is divided in 9 counting grids.  Large squares (1 mm² 
each) are divided into 16 group squares by double lines - 0,05 mm apart. The 
double lines form small squares, each with an area of 0,0025 mm². The chamber 
depth is 0,1 mm.  
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3.4.1 Chronic single pharmaceutical exposure 
 
A range-finding test was conducted to determine the range of concentrations for the 
definitive test. The final experimental design consisted of one daphnid per test 
chamber and 5 test chambers per treatment level. 6 treatments plus control and 7 
treatments plus control for propranolol and fluoxetine were performed, respectively. 
Concentrations were 0.25, 0.42, 0.71, 1.19, 2.00 mg/L for propranol and 0.025, 0.05, 
0.10, 0.20, 0.40, 0.80 mg/L for fluoxetine. Each experiment was repeated twice. 
 
 
3.4.2 Chronic mixture pharmaceutical exposure 
 
Chronic mixture compounds tests were carried out using the same experimental 
design described at point 3.3.2, using the propanolol 21-d EC50 and fluoxetine 21-d 
EC50 calculated from the single exposure study. Concentrations tested are illustrated 
in Fig. 3.9. Chronic mixture test design consisted in two replicates vessels for 
treatment (10 replicates for the control), one organism per glass container, and 
experiments repeated three times.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9. Fixed-ratio ray design adopted in the chronic mixture 
exposure experiments. Each point indicates the propranolol and 
fluoxetine concentration (mg/L) of an actually tested mixture. 
Along each ray, the proportion of ∑TU50 contributed by each of the 
two substances is constant, while ΣTU50 increases moving away 
from the origin of the axes. 
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3.5 Battery of Biomarkers 
 
 
Enzymatic activity of acetylcholinesterase and gluthatione s-transferase, and 
malondialdehyde production were evaluated. For each biomarker Daphnia magna 
response to a sub-chronic exposure to fluoxetine has been assessed. 
 
3.5.1 Experimental set up and 72-h Daphnia exposure 
 
To start the test we needed four-five days old daphnids, for this reason we isolated 
the adult Daphnia on Thursday, and the next day we transferred the newborns in a 
new tank. We fed them with half adult dose on Friday and the next Monday, and on 
Tuesday they were ready for test starting. 
Groups of 40 daphnids were exposed to 200 ml of test medium with different 
concentrations of fluoxetine in 500 ml beakers. Stock solution and diluitions were 
prepared using ISO water. Organisms were not fed during the test. 
After 72-h still mobile individuals were collected. Individuals from similar treatments 
were combined in eppendorf tubes and stored at -80°C for future enzyme analysis. 
 
3.5.2 Acetylcholinesterase (AChE) activity 
 
Daphnids were exposed to 0.2, 1.0 and 5.0 mg/L fluoxetine. Two replicates for each 
treatment level were performed. 
AChE activity has been assessed in accordance with the method described by 
Jemec et al. (2007) for Daphnia assays.  
Animals contained in one sample were manually homogenized for 3 min in 0.4 ml of 
50 mM homogenization phosphate pH 7.0 buffer, using a glass mini homogenizer. 
The homogenates were centrifuged for 15 min  at 15000 xg at 4°C.   
Enzyme activities in each sample were measured in quadruplicate using a microplate 
reader. The reaction mixture was prepared in 100 mM of phosphate pH 7.4 buffer 
containing acetylthiocholine chloride and 5,5’ dithiobis-2-nitrobenzoic acid (DTNB) at 
a final concentrations of 1 mM and 0.5 mM, respectively. 100 µl of protein surnatant 
were added to start the reaction, which was followed spectrophotometrically at 412 
nm at 25°C for 15 min. Total protein content in the supernatant fraction was 
measured according to Lowry et al. (1951). AChE activity was expressed  in nmol 
min-1 mg-1 protein. 
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3.5.3 Malondialdehyde (MDA) assay 
 
Daphnids were exposed to 1.0 and 5.0 mg/L fluoxetine with four and three replicates 
for treatment level respectively, six replicates for control. 
In order to verify the applicability of this test on Daphnia magna we performed also a 
positive control with chromium. We tested 0.040 and 0.200 mg/L concentrations of 
chromium in the form of potassium dichromate. Four replicates for each treatment 
level.  
MDA content was used to assess lipid peroxidation and was carried out following the 
test described by Banni et al. (2007) with slight modifications for Daphnia.  
Animals contained in one sample were treated with two series of 30 s ultrasonication 
(using an XL Heat System Ultrasonic Processor) in 0.250 ml of 20 mM Tris–HCl pH 
7.4 containing 0.1% β-mercaptoethanol and then centrifuged at 10000 xg for 20 min 
at 4°C. The supernatants obtained were used for the determination of MDA content: 
samples were incubated for 40 min in 5 mM methanol/1-methyl-2-
phenylindoleinacetonitrile and 6% HCl at 45°C, and subsequently centrifuged at 
15000 xg for 10 min at room temperature. Enzyme activities in each sample were 
measured in triplicate using a microplate reader. Absorbance was read 
spectrophotometrically at 586 nm against a standard curve of 1,1,3,3-
tetramethoxypropan (TMOP) treated in an identical manner. Total protein content in 
the supernatant fraction was measured according to Lowry et al. (1951) and the final 
results were expressed as nmol mg-1 protein. 
 
 
3.5.4 Glutathione S-transferase (GST) activity 
 
Daphnids were exposed to 1.0 and 5.0 mg/L fluoxetine. Two replicates for each 
treatment level were performed, and the test was repeated twice. 
Animals contained in one sample were processed with two series of 30 s 
ultrasonication in 0.2 ml of 50 mM potassium–phosphate buffer (KPB), pH 7.0 
containing 0.5 mM Na2EDTA following the protocol reported by Mimeault et al. 
(2006). The samples were then centrifuged for 15 min  at 15000 xg at 4°C.   
Surnatant was withdrawn and used for the determination of content of GST activity: 
enzyme activities in each sample were measured in quadruplicate using a microplate 
reader. 10 µl of protein supernatant was added to start the reaction. Glutathione S-
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transferase (GST) activity was determined by measuring the increase in absorbance 
at 340 nm due to the conjugation of 1-chloro-2,4-dinitrobenzene (CDNB) with 
reduced glutathione (GSH). The reaction was followed for 10 min and the total 
protein content in the supernatant fraction was measured according to Lowry et al. 
(1951). GST activity was expressed as nmol min-1 mg-1 protein. 
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3.6 Statistical Analysis 
 
 
3.6.1 Single compounds exposure 
 
Data from single exposures (pharmaceuticals and potassium dichromate) were 
analyzed using non-linear regression (Levenberg-Marquardt estimation method) as 
implemented in the commercial software Statistica (Statsoft, Tulsa, OK, USA). The 
EC50 and their confidence intervals were estimated by fitting the data from each 
experiment to the logistic model:  









EC50
1
c
max
y  (1) 
 
where y is the endpoint value (number of active individuals for the acute test, number 
of newborns/adult for the chronic test), max is the maximum expected endpoint 
value, when the concentration of the pharmaceutical is zero, C is the exposure 
concentration of the pharmaceutical, EC50  is the pharmaceutical concentration at 
which y = 0.5.max and β is a slope parameter. 
Regression was calculated in logarithmic scale and reconverted in mg/L. 
 
 
3.6.2 Mixture pharmaceutical exposure: MixTox tool 
 
Data from binary mixtures exposures were analyzed using the MixTox approach 
(Jonker at al., 2005), as implemented for binary mixtures in a Microsoft® Excel 
spreadsheet made available online by the Centre for Ecology & Hydrology of the UK 
Natural Environment Research Council at: 
http://www.ceh.ac.uk/products/stats/mixturetoxicity-analysistools.html.   
Here just a few key points, essential to understand the present results, are reported. 
See Jonker et al. (2005) and the documentation available at the above web page for 
a complete discussion.  
As already explained concentration addition (CA) was chosen as the reference model 
here. Concentration addition occurs for a mixture if the following relationship holds:  
1
EC

i i
i
x
c
  (2) 
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Where ci denotes the concentration of chemical i in the mixture, and ECxi is the 
concentration of chemical i solely that results in the same effect (x%) as the mixture.  
The quotient ci/ECxi is the toxic unit (TUxi ) and quantiﬁes the relative contribution to 
toxicity of the individual chemical i in  the mixture. 
In particular, for a binary mixture, equation 2 becomes:  
 
1
ECEC 2
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x
c
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c
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Assuming a logistic concentration-response relationship (equation 1), ECxi can be 
rewritten as the inversed function:  
 
i
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ymax
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Were y is the actual endpoint value (e.g. number of active individuals, number of 
newborns) that corresponds to a x% effect.  
Parameters of equation 3, i.e. EC501, EC502, β1, β2 and max, were estimated from 
the data of the mixture experiments, by iterative methods, using the “solver” facility of 
Microsoft Excel (Newton algorithm).  
Equation 3 represents the reference CA model in the absence of interaction between 
the chemicals and can be generalized to take interaction into account:  
 
 Gexp
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2
1
1
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The quantity G is referred to as the deviation function and describe if and how 
interaction between chemicals causes a deviation from the base reference model.  
If G = 0, equation 5 reduces to equation 3, i.e. to the reference CA model.  
Synergism or antagonism (S/A) can be described by the following deviation function: 
 
21zazG   (6) 
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were zi is the  relative amount of TU50 of chemical i in the mixture. i.e.:  
 
21 5050
50
TUTU
TU
z ii

  (7) 
 
 
This deviation function describes antagonism when parameter a is positive and 
synergism when a is negative, see table 3.3. If a = 0, then also G = 0 and there is no 
interaction between the two chemicals. 
As previously done for the reference CA model, parameters for the S/A model, i.e. 
EC501, EC502, β1, β2 max and a, were estimated from the same data of the mixture 
experiments, using the “solver” facility of Microsoft Excel.  
To verify if the S/A model provided a significantly better fit to the data than the 
reference CA model a likehood ratio test was performed. The test statistic was: 
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Were n is the number of observations, SSCA the sum of squared residuals from the 
reference CA model and SSS/A the sum of squared residuals from the S/A model. The 
statistic was compared to the χ2 distribution with one degree of freedom, which is the 
distribution of X2 if H0: a = 0 is true (the number of degrees of freedoms is the 
difference in the number of parameters between the two models). Antagonistic or 
synergistic effect has been considered significant if P < 0.05.  
The overall antagonistic or synergistic deviation can be made ratio dependent (DR) 
by including a second parameter in the deviation function, as follows: 
 
  2111 zzzbaG   (9) 
 
 
In this equation, the overall antagonistic or synergistic deviation changes with the 
proportion of chemical 1 in the mixture, where b1 determines the magnitude of 
change.  
Parameters for the DR model, i.e. EC501, EC502, β1, β2 max a and b1, were 
estimated. The DR model was then compared to both the CA and the S/A model, by 
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two likelihood ratio tests, to verify if provided a significantly better fit to the data, 
similarly to the already described comparison between CA and S/A models. 
To describe synergism and antagonism depending on the dose level, the basic 
deviation function (equation 6) is extended as:  
 
   2121 50501 zzTUTUbaG DL   (10) 
 
 
In this equation, the value of a indicates the deviation at low total concentrations, 
while the value of bDL indicates at what dose level the deviation changes (i.e., from 
antagonism to synergism or viceversa). 
Similarly to the DR model, parameters of the DL model, including bDL were estimated 
and the model was compared to the CA and S/A models by likelihood ratio tests. DR 
and DL models are not directly comparable to each other in this way, since they are 
not nested (i.e. neither is a special case of the other).  
 
 
 
 
 
 
 
 
 
 
Table 3.3. Interpretation of additional parameters substituited into the Concentration Addition (CA) and Indipendent 
Action (IA) reference models that define the functional form of the deviation pattern. 
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This procedure is summary into the following diagram (Fig. 3.10) :  
 
 
 
 
 
 
 
 
 
 
 
 
We used a Microsoft® Excel (Redmond, WA, USA) spreadsheet delineated by 
Jonker et al., distribuited in the NoMiracle-Project (version of spreadsheet setup, a 
manual, and an example data set are available at 
http://www.ceh.ac.uk/sections/er/csvendsen.html and the Solver Function (Newton 
Algorithm) in Microsoft® Excel which allowed to estimate the parameters in the 
different models. This phase consists of the application of the logistic model to the 
concentration-response data for the single pharmaceuticals (100% PRP – 0% FLX 
and 0% PRP – 100% FLX). As initial values of the parameters than those obtained 
from previous experiments on acute single pharmaceuticals exposure (paragraph 
4.1.2) were used. Starting from these initial values, new estimates based on 
experimental data were calculated. These results are independent of the nature of 
the interaction between the two substances, since they are obtained separately for 
each of the two substances, in the absence of the other. The statistical significance of 
any improvement compared to the basic CA model was assessed using chi-square 
(λ2) test as described by Jonker et al. (2005). 
  
Fig. 3.10. Flowchart of binary mixture development from the CA model. 
60 
 
3.6.3 Biomarkers 
 
Results from analysis were analyzed using the R statistical package (free resource at 
www.r-project.org). Significant differences between exposed and control samples 
were determined using a one-way ANOVA, statistical difference was accepted when 
p < 0.05. For malondialdehyde content the results firstly were log-transformed and, 
after ANOVA analysis, Dunnet test was carried out to understand which treatments 
are different from the control.  
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4. Results 
 
 
4.1 Acute Immobilization Toxicity Test  
 
4.1.1 Acute test on reference toxicant (potassium dichromate) 
 
EC50 values obtained during the present study are 1.68, 1.67, 1.05, 1.42, 1.66, 1.43 
and 1.66 mg/L, which indicate that the sensitivity of the organisms used, even with a 
certain degree of variability, remains within the range considered acceptable by the 
protocol. Taking as example the experiment with 1.42 mg/L EC50, the number of still 
active organisms in each beaker after 24 h of exposure as a function of the 
concentration of potassium dichromate is shown in Fig. 4.1. In the same Fig. the 
logistic curve parameterized on experimental data is also shown. Data are well fitted 
by the model and the experimental points are distributed over all regions of the fitted 
curve. In correspondence with the two lower tested concentrations no immobilized 
individuals were observed; from 1.93 mg/L the number of immobilized increases 
rapidly to reach 100% immobilization. The EC50 is estimated at 1.42 mg/L (95% 
confidence interval: 1.39 - 1.46). This value is within the range 0.60 to 1.70 mg/L 
defined as a validity criterion by ISO 6341 (1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1. Acute test with potassium dichromate: relationship between the 
number of active organisms in each beaker after a 24 hour exposure and the 
log10 of the concentration of the tested substance in µg/L. The dots represent 
the experimental data, while the continuous line represents the fitted logistic 
curve used to estimate the EC50. 
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4.1.2 Acute single pharmaceutical exposure 
 
Fig.s 4.2a, b, c; 4.3a, b, c; and 4.4a, b shown here below report the concentration-
effect curves for the three substances in the three esperiments: 
a) 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
c)  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2. First (a), second (b) and third (c) acute test with propranolol: 
relationship between the number of active organisms in each beaker after a 
48 hour exposure and the log10 of the concentrations of the test substance in 
µg/L. The dots represent the experimental data while the continuous line 
represents the fitted logistic curve used to estimate the EC50. 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3. First (a), second (b) and third (c) acute test with fluoxetine: relationship between 
the number of active organisms in each beaker after a 48 hour exposure and the log10 of 
the concentrations of the test substance in µg/L. The dots represent the experimental 
data while the continuous line represents the fitted logistic curve used to estimate the 
EC50. 
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a)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4.  First (a) and second (b) acute test with carbamazepine: relationship between 
the number of active organisms in each beaker after a 48 hour exposure and the log10 
of the concentrations of the test substance in µg/L. The dots represent the 
experimental data while the continuous line represents the fitted logistic curve used 
to estimate the EC50. 
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Clear dose-response relationships were observed in all single-chemical experiments: 
the number of active (non immobilized) organisms decreased with the increse of 
chemical concentration. EC50 values obtained from each single-chemical experiment 
are reported in Table 4.1. 
 
Table 4.1. Median effective concentration (EC50) values calculated for the single pharmaceuticals in the single-
chemical  acute exposure toxicity tests with D. magna. Confidence Limits 95% (CL) are shown in parentheses. 
 Substances 
 
Propranolol (mg/L) 
EC50 (CL) 
Fluoxetine (mg/L) 
EC50 (CL) 
Carbamazepine (mg/L) 
EC50 (CL) 
1
st 
experiment 7.3 (6.4 - 8.3) 9.1 (6.3 - 13.2) 105.5 (104.0 - 107.1) 
2
nd
 experiment 7.0 (6.1 - 8.1) 6.4 (3.9 - 10.5) 103.3 (101.7 – 105.0) 
3
rd
 experiment 6.5 (5.3 - 7.8) 7.6 (6.7 - 8.7)  
 
 
 
4.1.3 Acute mixture exposure 
 
The number of active organisms after the 48 h exposure as a function of total toxic 
units (∑TU50), and of the percentage of propranolol and fluoxetine in the mixtures, 
are presented in Fig. 4.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5. Number of active organisms as a  function of the concentration of the mixtures expressed as total 
toxic units (∑TU50). Each point represents the average of six experimental replicates. The different lines 
represent different percentages of propranolol and fluoxetine in the mixtures. 
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This graph shows how the lines representing the concentration-response relationship 
for the single pharmaceuticals (100% and 0% propranolol) are below the lines that 
represent the concentration-response relationship for the mixtures. This means that, 
for a given concentration in terms of ∑TU50, the number of active organisms is 
higher for mixtures than for the two single substances. In other words, for the same 
∑TU50, the mixtures appear to be less toxic than the single pharmaceuticals. 
Table 4.2 shows the results of the first phase of the data analysis performed using 
the implementation of MixTox in Excel and parameter of the logistic models are 
shown. The value of SSres for fluoxetine is much lower than that for propanolol, 
which means that the experimental data for fluoxetine are better adapted to the 
logistic model. 
 
Table 0.2. Application of MixTox to the chronic test of mixtures of propranolol and fluoxetine. Results for the two single 
substances: the parameters of the logistic model estimated using a nonlinear regression, implemented using the Solver 
function in Excel. The max parameter corresponds to the total number of organisms exposed at each concentration and 
to the number of mobile organisms in the control treatment. 
 
Afterwards, using the experimental data relative to the single substances and to all 
the mixtures, parameters for the concentration addition (CA) reference model,, 
synergism or antagonism (S/A), dose ratio dependent (DR) and dose level dependent 
(DL), have been estimated (Table 4.3). The parameters values for the single 
substances (Table 4.2) were used as initial values for the iterative estimation of the 
CA model. For the other models, the values obtained for the immediately simpler 
model were used as initial values: parameters from the CA model were used for the 
S/A model and, on their turn, parameters from the S/A model were used for the DR 
and the DL models.  
 
 
 
 
 
max β EC50 (mg/L) SSres 
Propranolol 
 
30 
 
3.59 8.19 25.98 
Fluoxetine 30 3.37 6.10 2.22 
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Table 4.3. MixTox output for the effects of mixtures of propranolol plus fluoxetine on the number of active organisms 
after a 48 h exposure. The parameters for the alternative models and the test for detecting of the model which best fits 
the experimental data are reported 
 
 
Table 4.3 shows the values returned by the application of MixTox for each model 
investigated. The SSres value decreases from the CA to the S/A model. SSres is 
further reduced also from S/A to DR and slightly from S/A to DL. Furthermore, the χ2 
test indicates that the S/A model fits the data significantly better than the CA model. 
Moreover the χ2 test indicates that, for both DR and DL that, while the improvement 
compared to the CA model is significant, the improvement with respect to S/A is not 
significant. Therefore, the application of MixTox to experimental data indicates that 
the model that best represents the data is the synergism/antagonism (S/A). Since the 
estimate for the a parameter is positive (a > 0), fluoxetine and propranolol act as 
antagonistic substances on D. magna immobilization (see Table 3.3). 
                                    models 
 CA S/A  DR   DL  
Max 30 30  30   30  
β PRP 2.82 3.05  3.06   2.95  
β FLX 2.90 3.20  3.20   3.07  
EC50 PRP 9.47 7.81  8.14   7.79  
EC50 FLX 7.73 6.51  6.17   6.49  
a  1.55  2.72   1.99  
b    -2.44   0.14  
SSres 379 213  193  
 212  
 
χ2 test 
   
CA 
vs DR 
S/A 
vs DR 
 
CA 
vs DL 
S/A 
vs DL 
N= 26         
df  1  2 1  2 1 
χ2   14.99  17.56 2.57  15.13 0.14 
P  0.0001  0.0002 0.1092  0.0005 0.7062 
Significance  ***  *** N.S.  *** N.S. 
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a)                                                                                          b) 
 
 
c)                                                                                          d)  
 
 
 
 
 
Fig. 4.5 is a graphical comparison of the performances of the reference CA model 
and the S/A model. Fig. 4.5a shows the number of active organisms predicted by CA, 
as a function of the observed number of active organisms. Fig. 4.5c shows the same 
for S/A. In Fig. 4.5c most of the points representing the model's predictions for 
individual pharmaceuticals are above the line, which means that the number of 
newborns is overestimated for single pharmaceuticals and underestimated for 
mixtures. In the S/A model, there is still this systematic aspect, but individual 
substances and mixture points are better distributed. In fact in general, all points and 
especially those related to the single substances tend to get closer to the line which 
Fig. 4.5. Predicted number of active organisms as a function of the observed number of active organisms for: a) CA 
model, c) S/A model. The line that cuts diagonally across the graphs indicates perfect agreement between model 
predictions and experimental observations. Residuals, i.e. differences beween observed and predicted numbers of 
newborns, for: b) CA model, d) S/A model. 
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represents the perfect agreement between experimental observations and model 
predictions. This means that there is a clear improvement in the fit to the 
experimental data when the S/A model is used, in comparison to the CA model, as 
also indicated by the decrease in the SSres values. This latter aspect is clear from Fig. 
4.10b, d,  were residuals, i.e. differences between observed and predicted active 
organisms, are represented as a function of ∑TU50 (mixtures data only).  
 
To illustrate the differences between the two models, Fig.s 4.6a and 4.11b show, 
respectively for C/A and SA, the predicted percentage of active organisms as a 
function of the percentage of propranolol in the mixture and of ∑TU50, for CA and 
S/A respectively. In particular, the lines representing the number of newborns as a 
function of the percentage of propranolol are concave curves, for the S/A model. 
Concavity is more pronounced for mixtures with ∑TU50 = 1 and more flattened for 
mixtures with higher or lower concentrations. This indicates that, for the same value 
of ∑TU50, mixtures with different percentages of the two pharmaceuticals have 
different effects. The single substances cause a greater reduction in  the number of 
newborns compared to mixtures in which both pharmaceuticals are present. In 
particular for mixtures 1 UT, the maximum of the curve is exactly at 50 % propranolol 
(i.e. 50% fluoxetine), indicating for this combination, the lowest reduction in the 
number of newborns compared to the control. For ∑TU50 = 1, the number of active 
organisms at 100% propranolol and at 0% propranolol (i.e. 100% fluoxetine) is about 
50 % both for CA and S/A. This value is exactly half the value of the max parameter 
in percentage, which means 15 out of 30 active organisms. This was expected, since, 
independently from the interactions between two chemicals, 1 TU of one of them, in 
the absence of the other corresponds to the EC50 and, as such, causes a 50% 
effect, in this case a 50% immobilization.  
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6. Prediction of the CA (a) and S/A (b) models fitted to the experimental data: 
percentage of active organisms as a function of the percentage of propranolol 
present in the mixture (the percentage of fluoxetine is the complement to 100 %). 
The lines of different colors represent different total concentrations of the mixture 
(∑TU50).  
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4.2 21-d Chronic Reproduction Toxicity Test 
 
 
4.2.1 Chronic single pharmaceuticals exposure 
 
The number of newborns produced by each parent organism over 21 days of 
exposure as a function of the concentration of propranolol for the two experiments 
are shown in Fig. 4.7a, b. In the same Fig.s the logistic curves fitted to the 
experimental data are also shown. Although in the first test the slope of the curve is 
higher, in both tests here is a similar reduction of the average number of births for 
Daphnia while pharmaceutical concentration increase. 
Both tests are considered valid as fulfilling the conditions defined by the OECD 
guidelines 211 (2008) and ISO 10706 (2000) (chapter 3.4). 
a) 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7. First (a) and second (b) chronic test with propranolol: relationship 
between the number of newborns produced by each parent organisms over 21 d 
exposure and the log10 of the concentrations of the test substance in µg/L. The 
dots represent the experimental data while the continuous line represents the 
fitted logistic curve used to estimate the EC50. 
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The number of newborns produced by each parent organism over 21 days of 
exposure as a function of the concentration of fluoxetine is shown in Fig. 4.8a, b. In 
the same figure the logistic curve fitted on experimental data is also shown.  
As observed from the figures, the number of newborns, differently from the test with 
propranolol, decreases with increasing concentration of fluoxetine only at the highest 
tested concentrations. A slightly higher number of newborns was observed in the 
presence of a low concentration of fluoxetine (0.03 mg/L) compared to the control. 
These differences, however, are not statistically significant when evaluated using the 
Dunnet’s test. In both tests, the EC50 calculated shows similar values and in general, 
the curves of the two experiments are similar with a slightly different slope. 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8. First (a) and second (b) chronic test with fluoxetine: relationship 
between the number of newborns produced by each parent organisms over 
21 d exposure and the log10 of the concentrations of the test substance in 
µg/L. The dots represent the experimental data while the continuous line 
represents the fitted logistic curve used to estimate the EC50. 
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The EC50 values for the number of newborns produced by each parent organism are 
shown in Table 4.4. EC50 of fluoxetine is four times lower than that of propranolol, 
i.e. 0.74 and 0.24 mg/L for propranolol and fluoxetine, respectively. The average 
EC50 have been used for the calculation of concentrations expressed as total units 
toxic for the mixture tests, while the values of the slope of the curve and the highest 
value observed (top) have been used as starting values for the MixTox analysis.    
 
Table 4.4. Median effective concentration (EC50) values calculated for the single pharmaceuticals in the single chronic 
exposures toxicity tests with D. magna. Confidence Limits 95% (CL) are shown in parentheses. 
 
Propranolol (mg/L) 
EC50 (CL) 
Fluoxetine (mg/L) 
EC50 (CL) 
1st experiment 0.883 (0.731-1.067) 0.245 (0.193-0.309) 
2nd experiment 0.592 (0.480-0.729) 0.232 (0.203-0.266) 
 
 
 
4.2.2 Chronic mixture exposure 
 
In the chronic test with mixtures of propranolol plus fluoxetine Daphnia are exposed 
for 21 days to different concentration proportions expressed in toxic unit of the two 
pharmaceuticals. In Fig. 4.9 are presented the results of experimental tests in terms 
of average number of newborns produced by a single Daphnia as a function of the 
concentration of mixtures expressed in total toxic units, and the percentage of 
propranolol in the mixtures.  
This graph shows how the lines representing the relationship concentration-response 
for the two single pharmaceuticals (100% and 0% propranolol) are below the lines 
that represent the relationship concentration-response of the mixtures. This means 
that, for a given concentration in terms of toxic units, the number of newborns is 
higher for mixtures than for the two single substances. In other words, always at the 
same concentration, the mixtures appear to be less toxic than the pharmaceuticals 
alone. 
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Table 4.5 shows the results of data analysis through the implementation of MixTox in 
Excel. This phase consists of the application of the logistic model to data related only 
to a single pharmaceutical, either propranolol or fluoxetine (100% PRP and 100% 
FLX). As initial values of the parameters were used those obtained from previous 
experiments on chronic single pharmaceuticals exposure (section 4.2.1). Starting 
from these initial values, new estimates based on experimental data were calculated 
by the Solver function with iterative methods. These results are independent of the 
nature of the interaction between the two substances, since they are obtained 
separately for each of the two substances, in the absence of the other one. 
 
Table 4.5. Application of MixTox to the chronic test of mixtures of propranolol plus fluoxetine. Results for the two single 
substances: the parameters of the logistic model estimated using nonlinear regression, implemented using the Solver 
function in Excel. 
 Max 
(No newborns 
per Daphnia) 
β EC50 (mg/L) SSres 
Propranolol 68.74 2.78 0.909 100.04 
Fluoxetine 68.74 2.60 0.216 163.74 
Fig. 4.9. Number of offspring per individual Daphnia as a function of the concentration of the mixtures 
expressed in total toxic units (∑TU50). Each point represents the average of six experimental replicates. The 
different lines represent different percentages of propranolol and fluoxetine in the mixtures.  
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Afterwards, using the experimental data relative to individual substances and to 
mixtures, parameters (explained in section 3.6.2) for the CA reference model, S/A, 
DR and DL models have been estimated. For the CA model the parameters related 
to individual substances were used as initial values for the iterative process of 
estimation (Table 4.6). For further models, values previously obtained for the model 
immediately easier were used as initial values, as previously explained (section 
4.1.3). 
 
Table 4.6. MixTox output for the effects of mixtures of propranolol plus fluoxetine on the reproduction of Daphnia 
magna (number of neonates produced by a female after 21 d exposure). The parameters for the alternative models and 
the test for the detection of the model that best fit the experimental data are reported. 
                               models 
 CA S/A  DR   DL  
Max 62.51 63.96  63.61  
 
63.43 
 
β PRP 2.44 3.07  3.10   2.84  
β FLX 4.25 3.40  3.51   3.15  
EC50 PRP 1.354 1.002  0.978   1.016  
EC50 FLX 0.283 0.228  0.238   0.228  
a  1.70  0.91   3.03  
b    1.59   0.31  
SSres 1443 607  570  
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χ2 Test  
 
CA 
vs S/A   
CA 
vs DR 
S/A 
vs DR 
 
CA 
vs DL 
S/A  
vs DL 
N= 26         
df  1  2 1  2 1 
χ2 value  22.52  24.15 1.64  23.91 1.39 
P  0.000  0.000 0.200  0.000 0.238 
Significance  ***  *** N.S.  *** N.S. 
 
Table 4.6 shows the values returned by the application of MixTox for each model 
investigated. A further decrease in the value of SSres from CA to S/A application can 
be observed. The value of SSres is reduced also from S/A to both DR and DL 
application. Furthermore, the λ2 test indicates that the model S/A fits the data 
significantly better than the CA model, for both DR and for DL the λ2 test indicates 
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that while the improvement compared to the CA model is significant, the 
improvement with respect to S/A is not significant. Therefore, the application of 
MixTox to experimental data indicates that the model that best represents the data is 
the synergism/antagonism (S/A). Compared to Table 3.3 of section 3.6.2 it is possible 
to determine the value of the parameters a, which is greater than zero, indicating that 
in the mixture the two pharmaceuticals have an antagonism behavior. 
 
a)                                                                                         b) 
 
 
 
 
 
 
 
 
 
c)                                                                                          d) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.10 is a graphical comparison of the performances of the reference CA model 
and the S/A model. Fig. 4.10a shows the number of newborns predicted by CA, as a 
function of the observed number of newborns. Fig. 4.10c shows the same for S/A. 
There is a clear improvement in the fit to the experimental data when the S/A model 
is used, in comparison to the CA model: the points tend generally to get closer to the 
Fig. 4.10. Predicted number of newborns per Daphnia as a function of the observed number of newborns for: a) CA 
model, c) S/A model. The line that cuts diagonally across the graphs indicates perfect agreement between model 
predictions and experimental observations. Residuals, i.e. differences beween observed and predicted numbers of 
newborns, for: b) CA model, d) S/A model. 
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line which represents the perfect agreement between experimental observations and 
model predictions, as already indicated by the decrease in the SSres values. 
Furthermore, in figure a, most of the points that represent the model's predictions for 
mixtures are below the line that indicates the perfect agreement, while most of the 
points representing the model's predictions for individual pharmaceuticals are above 
the line. So it is clear that the number of newborns is overestimated for single 
pharmaceuticals and underestimated for mixtures. In the S/A model, this systematic 
aspect is absent and individual substances and mixture points are better distributed 
around the line. This aspect is clear also from Fig. 4.10b, d,  were residuals, i.e. 
differences between observed and predicted number of newborns, are represented 
as a function of ∑TU50 (mixtures data only).  
To illustrate the differences between the two models, Fig. 4.11a and 4.11b show, 
respectively for C/A and SA, the predicted number of newborns per parent organism 
as a function of the percentage of propranolol in the mixture and of ∑TU50, for CA 
and S/A, respectively. In particular, the lines representing the number of newborns as 
a function of the percentage of propranolol are concave curves, for the S/A model. 
Concavity is more pronounced for mixtures with ∑TU50 = 1and more flattened for 
mixtures with higher or lower concentrations of propranolol. This indicates that, for 
the same value of ∑TU50, mixtures with different percentages of the two 
pharmaceuticals have different effects. The single substances cause a greater 
reduction in  the number of newborns compared to mixtures in which both 
pharmaceuticals are present. In particular for mixtures 1 UT, the maximum of the 
curve is exactly at 50 % propranolol, indicating for this combination, the lowest 
reduction in the number of newborns compared to the control For ∑TU50 = 1, the 
number of newborns for parent organism at 100% propranolol and at 0% propranolol 
(i.e. 100% fluoxetine) is about 30 both for CA and S/A. This value is exactly half the 
value of the max parameter. This was expected, since, independently from the 
interactions between two chemicals, 1 TU of one of them, in the absence of the other 
corresponds to the EC50 and, as such, causes a 50% effect, in this case a 50% 
inhibition of reproduction.  
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.11. Prediction of the CA (a) and S/A (b) models fitted to the experimental data: 
average number of newborns per individual as a function of the percentage of 
propranolol present in the mixture (the percentage of fluoxetine is the complement to 
100 %). The lines of different colors represent different total concentrations of the 
mixture (∑TU50). 
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4.3 Battery of biomarkers 
 
 
 
4.3.1 Acetylcholinesterase activity 
 
Daphnia AChE activitiy in control animals was 1.26 nmol/min/mg protein. The 
enzyme activity, in Daphnia exposed to 0.2, 1.0 and 5.0 mg/L fluoxetine was not 
significantly different from controls (p>0.5) (Fig. 4.12), suggesting no neuroactive 
effects. 
 
 
  
         Fig. 4.12. AChE activity in Daphnia exposed to fluoxetine. 
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4.3.2 Malondialdehyde assay  
 
The effect of fluoxetine on Daphnia MDA content is illustrated in Fig. 4.13. The MDA 
content  was about 0.530 nmol/mg of protein for control organisms; ANOVA analysis 
indicates that there are significant differences between treatments (p< 0.01). 
Dunnet's test indicates that 0.04 mg/L of chromium(VI) is the only treatment 
significantly different from control with p< 0.01. MDA content, reflecting oxidative 
stress, was not change in Daphnia exposed to fluoxetine, while a three-fold increase 
in MDA was found in organisms exposed to chromium(VI) which is a known oxidative 
chemical. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.13. MDA content in Daphnia exposed to fluoxetine and chromium(VI). Asterisk indicates a value 
significantly different from control: ** p < 0.01. 
** 
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4.3.3 Glutathione S-transferase activity  
 
GST activity in the control treatment was about 134 nmol/min/mg protein. Slightly 
higher GST activities, which would represent an activation of detoxification reactions 
occurring after pharmaceutical exposure, were observed in Daphnia exposed to 1.0 
and 5.0 mg/L fluoxetine (Fig. 4.14), although the differences from the control were not 
significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                Fig. 4.14. GST activity in Daphnia exposed to fluoxetine. 
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5. Discussion 
 
 
5.1 Single Toxicants Exposure 
 
 
5.1.1 24-h acute immobilization toxicity test with reference toxicant 
(potassium dichromate) 
 
Repeatedly, throughout this study, the sensitivity of Daphnia magna was assessed by 
24 h immobilization tests with the reference substance potassium dichromate.  
To satisfy the validity criteria dictated by ISO (2012), EC50 values should fall in the 
range 0.6 mg/L to 2.1 mg/L. EC50 values estimated throughout the study ranged 
from 1.05 to 1.68 mg/L indicating that the sensitivity of the organisms used, even with 
a certain degree of variability, remained within the range considered acceptable. 
In our experience, the chemical composition of the dilution water has a strong 
influence on potassium dichromate toxicity. In fact, in experiments previously carried 
out in our laboratory, according to the same procedures and using the same 
exposure conditions except that Guizza water (see section 3.1.1) was adopted as the 
test medium, all the estimates EC50 (0.54 mg/L, 0.61 mg/L, 0.50 mg/L) were below 
or just slightly above the lower limit set by the protocol. 
 
 
5.1.2 48-h acute immobilization toxicity test on pharmaceuticals 
 
Acute  tests with single pharmaceuticals were carried out in order to identify the 
EC50 values. This information for propranolol and fluoxetine was used to calculate 
concentrations in terms of toxic units and as the basis to properly design the acute 
mixtures exposure experiment. 
The three experiments with propranolol alone provided EC50s in the range 6.5 to 7.3 
mg/L. Taking into consideration also the single pharmaceutical EC50 values 
estimated in the mixture tests when propranolol was added as single pharmaceutical, 
the values ranged from 6.5 to 9.5 mg/L.  
Stanley et al. (2006) found an EC50 of 1.67 mg/L for D. magna exposed to 
propranolol for 48hours, which is roughly equivalent to the values 1.6 and 2.75 mg/L 
reported by Huggett et al. (2002) and Ferrari et al. (2004), respectively. These values 
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are  lower than those found in the present study and this may be due to different 
procedures and different media used during the tests. 
Regarding fluoxetine, the EC50 values provided by the experiments, considering also 
the single pharmaceutical EC50 found in the mixture tests, ranged from 7.6 to 9.1 
mg/L.  
Brooks et al. (2003) found a LC50 value (50% Lethal Concentration) of 0.820 mg/L 
for D. magna exposed to fluoxetine for 48 hours. Also in this case, the difference in 
comparison with this study might be explained by the use of a different reconstituted 
hard water (US EPA, 1991). Our hypothesis is that the substances can react in 
different way with the dissolved salts as already explained in section 5.1.1. 
Acute toxicities of propranolol and fluoxetine appear to be similar, when we compare 
the results of the present study. Even though there is not complete agreement with 
previous reports, it is confirmed that both pharmaceuticals exert acute effects only at 
levels that are several orders of magnitude higher than environmental concentrations, 
which range from ng/L to low µg/L, according to the literature. The only possible 
exceptions, at a local scale, could be accidental releases or improper disposals.  
Regarding carbamazepine, the experiments provided two EC50 values, of 105.5 and 
103.3 mg/L. Jos et al. (2003) exposing D. magna to carbamazepine for 48 hours 
found an EC50 of 97.8 mg/L; Kim et al. (2007) reported an EC50 value > 100 mg/L. 
Both results are in line with ours.  
The acute EC50 values found in the present and previous studies are considerably 
higher than the environmental concentrations of carbamazepine, up to 1075 ng/L in 
surface water (Heberer, 2002) and 6.3 µg/L in municipal STP effluents (Ternes, 
1998). However, it is important to remember that the highest removal efficiency for 
carbamazepine in a WWTP (Waste Water Treatment Plants) was 53%, observed by 
Paxéus (2004), while it is normally poorly removed (below 9%, Fent et al., 2006). 
Such low removal efficiency of carbamazepine can be explained by its properties. 
First, it is resistant to biodegradation at low concentrations. Stamatelatou et al. (2003) 
conducted a biodegradability test of carbamazepine in CH3COONa cultured activated 
sludge in both sea and fresh water. They observed no biodegradation of  
carbamazepine at an initial concentration of 0.5 mg/L in either sea or fresh water. In 
the classification scheme for pharmaceutical biodegradation, the removal status of 
carbamazepine is classified as ‘‘no removal” (Joss et al., 2006). Furthermore, it is 
hardly attached onto sludge. Its distribution coefficient between water and secondary 
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sludge (Kd) is 1.2 L kgss
-1 (Ternes et al., 2004), far from the value 500 L kgss
-1 
required for significant sorption onto sludge. Therefore the bulk of carbamazepine 
remains associated with the aqueous phase. Furthermore, Vernouillet et al. (2010) 
observed the ability of CBZ to bioaccumulate in aquatic organisms through food 
contamination, although the high concentration of CBZ (150 mg/L) used 
experimentally is unlikely to be found in the environment (Fent et al., 2006).  
We conclude that although water concentrations are lower than the EC50 
experimentally established, carbamazepine is pseudo-.persistent in the environment 
and able to bioaccumulate. Therefore, animals are chronically exposed to the 
pharmaceutical and studies on long term effects are advisable.  
 
 
5.1.3 21-d chronic reproduction toxicity test on pharmaceuticals 
 
Chronic tests with single pharmaceuticals were carried out in order to identify the 
EC50 values for reproduction. This information was used to calculate concentrations 
in terms of toxic units and as the basis to properly design the chronic mixtures 
exposure experiment. 
Single chemical experiments with propranolol provided two EC50 of 0.592 and 0.883 
mg/L. If we take into consideration also the single pharmaceutical EC50 found in the 
mixture tests the values becomes ranged from 0.592 to 0.909 mg/L.  
Experimental data showed that increasing the concentration of the substance, a 
decrease in reproduction occurred. Compared to the average number of newborns in 
the control treatment, a decrease in the number of offspring was observed even at 
the lowest tested concentrations: at 0.25 mg/L the reduction was 6 % and 19 % for 
the first and second tests, respectively. This is in contrast with Stanley et al. (2006), 
that observed a significant increases in reproduction at 0.05, 0.20 and 0.40 mg/L in 
D. magna  exposed to the racemic propranolol for 21 days. The mechanistic cause of 
this increase was unknown at that time (Stanley et al., 2006). On the contrary they 
detected a significant decrease in reproductive output at 0.8 mg/L and values similar 
to the control at concentration of 0.10 mg/L.  
Results in line with the present study are presented by Dzialowsky et al. (2006) who 
observed a significant decrease in reproduction in D. magna exposed to 0.11 and 
0.44 mg/L in subchronic 9-day tests. They also identified heart rate as the most 
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sensitive among the tested endpoints, since it decreased even at the lowest tested 
concentration (0.055 mg/L). 
Regarding fluoxetine, the chronic EC50 for reproduction ranged from 0.216 to 0.245 
mg/L, considering the single chemical experiments and the single chemical EC50 
from the mixtures experiment. These values are much lower than those found for 
propranolol. Comparing acute to chronic tests, the EC50 values decreased for both 
substances by one order of magnitude. However the greatest variation was observed 
for fluoxetine, for which the chronic EC50 was 30 fold smaller than the acute EC50. 
In addition, it is important to note that, while propranolol determined a monothonic 
decrease in reproduction with increasing concentration, the trend was not as regular 
for fluoxetine. In fact, at 0.025 mg/L, the lowest tested concentration, a slight increase 
in the number of newborns per D. magna was observed. In our study this result is not 
statistically significant, however the trend is in agreement with previous evidence that  
low concentrations of fluoxetine lead to hormesis; in particular an increase of 
reproductive output was observed. Fong (1998) reported that 0.036 mg/L fluoxetine 
increased zebra mussel fecundity, and Brooks et al. (2003) found that Ceriodaphnia 
dubia produced significantly more offspring when exposed to 0.056 mg/L fluoxetine. 
Flaherty and Dodson (2005) reported that 0.036 mg/L 30-d chronic fluoxetine 
exposure elicited a significant increase (3 times higher than control) in the total 
number of D. magna offspring produced. An increase in D. magna fecundity following 
chronic fluoxetine exposure may be an example of the phenomenon known as 
overcompensation hormesis, an adaptive response to low levels of stress that results 
in improved fitness for a finite period (Calabrese and Baldwin, 2002). 
Stanley et al. (2007) after exposing D. magna for 21 d to 0.01, 0.05, 0.1, 0.25, 0.5, 
1.0 mg/L R-, rac- and S-fluoxetine (nominal concentrations), identified 0.430, 0.429, 
0.444 mg/L respectively as the LOEC (Lowest Observed Effect Concentration, 
measured concetrations). For the pure enantiomers, but not for the racemic mixture, 
they also observed a minimal, not statistically significant, increase in the mean  
number of offspring produced per organisms at low concentrations: at 0.010 mg/L for 
R-fluoxetine and at 0.051 mg/L for S-fluoxetine (measured concentrations). 
This results are in agreement with our study and point out that hormetic effects of 
fluoxetine on reproduction deserve further clarifications. 
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5.2 Mixture exposure 
 
 
The experimental results of the acute and chronic mixture tests were analyzed by 
MixTox, a statistical approach devised to predict the combined effects of chemical 
and to identify the type of interaction among them. Mixtox can be applied only if all 
the single substances in the mixture show monotonic dose-response relationship. 
This holds in our case: increasing the concentrations of both pharmaceuticals, the 
toxic effect monotonically increased as well. In addition, although the lower 
concentrations of FLX in the mixture (0.030 and 0.042 mg/L) are indicated in the 
literature as the “hormesis zone” (section 5.1.3), according to our data the hormesis 
effect is not statistically significant, therefore excluded or at least negligible.  
 
The application of MixTox is based on the choice between two reference models: 
concentration addition (CA) and independent action (IA). In the present study the CA 
model was adopted, considering propranolol and fluoxetine to have similar mode of 
action (see section 1.3.4).  
The MixTox analysis detected an antagonism deviation from the conceptual model of 
Concentration Addition for both acute and chronic test.  
This has implications as to environmental risk assessment, were one of the major 
concerns is the possible amplification of effects when multiple contaminants, 
pharmaceuticals in particular, are present in the environment. In our particular case, 
the contrary was actually observed. We are aware that the experiments were 
performed in environmentally unrealistic conditions: mixtures in the aquatic 
environment will never be constituted only by two pharmaceuticals. In addition, the 
detected environmental concentrations are always much lower than those tested. 
These consideration, however, do not reduce the importance of the tests because 
they provide new information, also as a starting point for further exploration.  
One major issue raised in the present study was how well the reference models 
would predict joint effects of a chemical mixture, and how the MoA of compounds 
must be known before a clear decision on which conceptual model to use becomes 
useful. 
Franzellitti et al. (2013) with their studies on the mussel Mytilus galloprovincialis have 
considered both pharmaceuticals acting with the same MoA, and detected that the 
effects on mantle/gonads of mussels exposed to mixtures of fluoxetine + propranolol 
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were quite different than those exerted by the exposure to single chemicals. This 
finding was consistent with an antagonistic effect displayed by PROP on the 5-HT 
pathway in mantle/gonads as a result of a prevalent serotoninergic control in these 
tissues.  
The available knowledge on the mode of action of the two pharmaceuticals in D. 
magna has been increased by recent studies on membrane receptors, illustrated in 
section 1.3.4. Therefore, a hypothesis can be formulated to explain the mechanism 
underlying the antagonism between propranolol and fluoxetine. The therapeutic 
action of fluoxetine as a SSRI is to increase serotoninergic neurotransmission at 
synapses by blocking 5-HT reuptake transporters, thus increasing extracellular levels 
of 5-HT (Fong et al., 2003). Propranolol is an β-adrenergic receptor antagonist (Weir, 
2009), but it is also an effective antagonist for type 1 5-HT receptors (5-HT1), which 
are  negatively coupled to the cAMP transduction pathway (Alexander and Wood, 
1987).  
Studies on propranolol carried out in mussels show that, by blocking β-adrenergic 
receptors, PRP blocks the action of adrenergic agonists which increases cAMP, thus 
it indirectly decreases intracellular levels of cAMP (Franzellitti et al., 2011). By 
blocking 5-HT1 receptors, PRP prevents binding of serotonin on this class of 
receptors. Fluoxetine provokes an increase in the concentration of serotonin which in 
turn would cause a decrease in the concentration of intracellular cAMP through 5HT1 
receptors (Fazzino et al., 2009).  
In conclusion, both pharmaceuticals alone induce a decrease of cAMP levels.  This 
phenomenon could induce a decrease in reproduction; in fact cAMP pathway is 
involved in a variety of physiological functions related to reproduction as shown in 
mussels, i.e., it modulates the availability of energy for the development of the 
gonads thus being essential for the reproduction of mussels (Fabbri and Capuzzo, 
2010). In other bivalves, it is also well demonstrated that serotonin injection induces 
gamete releases (Fabbri and Capuzzo, 2010), again by acting on the cAMP 
pathways.  
Regarding the immobilization effect, it is widely demonstrated that cAMP is involved 
in modulation of motility. Specifically, an increase in cAMP level stimulates motility of 
flagellum (Negri et al. 1996) and vibratile cilia (Fabbri and Capuzzo, 2010), and also 
stimulates muscle contraction (Menezes-Rodrigues et al., 2013).  
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When propranolol and fluoxetine are present simultaneously, both compounds can 
affect the same molecular target, directly, FLX, by increasing the availability of the 
agonist molecules or indirectly, PRP, by binding to the receptor and preventing its 
occupation by the agonist. We may hypothesize that in Daphnia exposed to the 
mixture propranolol binds the 5-HT1 receptor and the effect of serotonin to decrease 
cAMP level induced by fluoxetine is reduced (fluoxetine would result less effective), 
thus a lower decrease in cAMP is observed (Fig. 5.1). 
 
 
a)                                                                    b)  
 
 
 
 
 
 
 
 
 
c)  
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 5.1. Representation of how  propranolol (a), fluoxetine (b) and the mixture propranolol +  fluoxetine (c) may 
affect cAMP pathway.    
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Although the adrenergic or serotoninergic receptors present in Daphnia are not 
known in details, we may hypothesize that the antagonism between propranolol and 
fluoxetine revealed in the mixture takes place in line with the effects described above, 
suggesting that a lower reduction of cAMP (due to the mixture exposure as above 
hypotesized) lead to a reduction of immobilization or a reduction of the reproduction 
decrease compared to the effects of single pharmaceuticals.  
Even though MixTox indicated that Fluoxetine and Propranolol act as antagonists in 
Daphnia and we proposed a possible mechanism, this result was not obvious in 
advance and different outcomes are possible for other species. For instance Drake 
and Gordon (1994) published a case study concerning a 53 years old man 
demonstrating that the addition of fluoxetine to his normal daily care for anxiety with 
propranolol caused a complete heart block. The hypothesis suggested by the authors 
was that since there is good evidence that 5-HT receptors are present in the human 
atrium, fluoxetine involves the enhancement of the action of serotonin compromising 
the atrio-ventricular conduction. 
We must admit that the two pharmaceuticals can have multiple mechanisms of 
action, and influence reproduction and heart functionality in different ways in different 
organisms, therefore we are not able to extrapolate which are the physiological 
mechanisms that determine the actual antagonism between the two pharmaceuticals 
in D. magna; however the above hypothesis appear plausible for what regards the 
receptors involved. 
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5.3 Biomarkers 
 
 
Before testing the effects of fluoxetine on AChE, MDA and GST on D. magna it was 
necessary to optimize the procedures and particularly the exposure conditions. It was 
very important to find the number of animals per sample that allowed an accurate 
measurement of the enzymatic activities. This number had to be a good compromise 
between the sensitivity of enzymatic determinations and costs (in money, time and 
human effort) needed to culture the daphnids required to run the experiment. 
Consequently, all further tests were performed on samples consisting of 40 
individuals aged 7-8 d at the end of the 72 h exposure. 
 
 
5.3.1 Acetylcholinesterase activity  
 
Literature data on the effects of fluoxetine on AChE on D. magna are not available. In 
our experimental conditions, no effect of fluoxetine on AChE was observed. AChE 
basal activity in unexposed animals was in agreement with Jemec et al. (2007). 
AChE activity is selectively inhibited by organophosphate and carbamates, but also 
metals can influence this enzyme (Ishaaya, 2001): in fact Diamantino et al. (2000) 
observed a significant inhibition of AChE activity in Daphnia magna exposed to 150 
µg/L Cr(VI) for 48 hours. However Jemec et al. (2007) observed no effect on AChE 
activity in organism exposed up to 280 µg/L Cr(VI) for 48 hours, while the AChE 
activity in animals exposed to low concentrations of Cd2+ increased slightly as a 
result of a possible hormesis. Jemec et al. (2007) supposed that there were no direct 
linkage between biomarkers and immobility of the organisms: several authors (Day 
and Scott, 1990; Jemec et al., 2007) have concluded that the immobility after acute 
exposure in this organisms is not always directly linked with the degree of the 
enzyme inhibition. Immobility were proportional (dose-response) to the concentration 
of the tested substances, while AChE activities were independent of the tested 
concentrations. Thus, in this case response of biochemical biomarkers were less 
sensitive than higher level endpoints (immobilization). Therefore, the applicability of 
this biomarker in routine acute toxicity tests is limited. On the other hand Jemec et al. 
(2008) reported that biochemical biomarker in chronic study were in some case 
equally or more sensitive than reproduction. This effect was more pronounced for 
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Cr(VI), which had more influenced the AChE after chronic exposure, while none was 
changed after acute exposure. For instance, AChE activity significantly decreased 
and increased in D. magna chronically exposed to concentrations above 35 µg/L of 
Cr6+ and to 0.082 µg/L of Cd2+, respectively.  
It is know that carbamates and organophosphates, widely used as active ingredients 
of insecticide formulations, are inhibitors of AChE. AChE inhibitors disrupt the nerve 
transmission by competitively binding to the esteric site of AChE (Fukuto, 1990), this 
inhibiting the breakdown of the neurotransmitter acetylcholine to acetate and choline. 
Accumulation of acetylcholine leads to paralysis (immobilization) and eventually to 
death (Boelsterli, 2007). D. magna is very sensitive to organophosphorous pesticides 
(Guilhermino et al., 1996), and it is widely used in aquatic risk assessment because 
often water bodies around agricultural fields receiving organophosphorous and 
carbamates pesticide treatments. Many studies demostrated that AChE activity in D. 
magna responds to a organophosphorous or carbamates exposure. For instance, 
Barata et al. (2004) in D. magna after 48 h exposure observed a significant decrease 
in AChE activity from a basal value of 3.5 nmol/min/mg protein to values < 1 
nmol/min/mg protein for the organophosphorus chlorpyrifos and malathion, and a 
value slight below 2 nmol/min/mg protein for the carbamate carbofuran pesticides. 
Studies reported above indicate that organophosphorus, carbamate and heavy 
metals can inhibit the AChE activity, however, also other environmental pollutants, 
such pharmaceuticals can inhibit AChE activity, for instance ibuprofen tested in 
bivalves by Milan et al. (2013). Regarding the response of AChE activity to fluoxetine, 
Munari et al. (2014) exposed clams for 7 days to 0, 1, 5, 25, 125 and 625 mg/L 
fluoxetine. AChE activity was shown to decrease significantly in the gills of clams 
exposed to 1 and 5 mg/L compared with controls. It is well known that AChE plays an 
important role in the functioning of the neuromuscular system by preventing 
continuous muscular contraction. Munari et al. tested the hypothesis that fluoxetine is 
neurotoxic to V. philippinarum. The results of their study partially support this 
hypothesis. Indeed, gill AChE activity decreased significantly in clams exposed to the 
lowest concentrations of fluoxetine, whereas enzyme activity returned to control 
values in clams exposed to the highest fluoxetine concentrations. Their controversial 
result was also recorded in a recent study on mussels (M. galloprovincialis) that were 
exposed to fluoxetine (75 ng/L) for 15 days (Gonzalez-Rey and Bebianno, 2013). In 
that study, SSRI FLX potential to cause neurotoxic effects response was tested by 
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assessing the activity of the essential neurotransmission modulator, enzyme 
acetylcholinesterase in mussel gills. The enzyme activity increased significantly after 
3 days of exposure, followed by progressive inhibition, reaching a significantly lower 
activity than controls after 15 days of exposure. In that experiment AChE activity was 
clearly altered. Conversely, AChE activity was shown to increase significantly in the 
muscle of crabs (C. maenas) after 7 days of exposure to fluoxetine (120 and 750 
mg/L) (Mesquita et al., 2011). 
Based on both reported studies and our results we can conclude that AChE activity 
may vary markedly in response to fluoxetine exposure, depending on the exposure 
concentration and duration and on the species and tissues analyzed. Since in our 
study no effect was observed and there is no further literature support, we presently 
exclude effects by fluoxetine on AChE activity. We also suggest that this biomarker is 
suitable for evaluating pesticide exposure, while its suitability for metals or 
pharmaceuticals need to be verified. 
We could assume that the applicability of this biomarker in D. magna  is limited and 
other studies to test lower concentration are essential.   
 
 
5.3.2 Malondialdehyde content 
 
The MDA content in control treatment was 0.530 ± 0.002 nmol/mg of protein. As well 
as AChE activity, also the MDA content did not change in Daphnia exposed to 
fluoxetine. To check the consistency of these results, a test with chromium(VI), which 
is a metal known to cause oxidative stress, was carried out. In fact D. magna 
exposed to 0.04 mg/L of chromium(VI) showed a significant increase in MDA content 
in comparison to the control. MDA content is considered a good general indicator of 
lipid peroxidation and its accumulation a marker for oxidative stress. When the 
antioxidant system response is compromised by an ROS excess, lipid peroxidation 
(LPO) occurs, resulting in the damage of phospholipids membrane (Valavanidis et 
al., 2006). Franzellitti et al. (2013) measured MDA content in mussels exposed for 7 
days to nominal 0.03, 0.3, 3, 30 and 300 ng/L fluoxetine and they observed a 
significant decrease in its content in digestive gland after treatment with 0.3 and 30 
ng/L fluoxetine. They explained that the lack of clear antioxidant responses in 
digestive gland can be a consequence of a preferential lysosomal sequestration of 
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fluoxetine, which in turn would prevent further cellular effects of the pharmaceutical, 
including lipid peroxidation. 
Galecki et al. (2009) measured MDA content in erythrocytes of depressed patient 
before and after a 3 month fluoxetine treatment. They observed that the MDA level 
was significantly higher in depressed patients (low levels of serotonin) before 
treatment (0.739 nmol/gHb) compared to the control group (0.549 nmol/gHb), while 
MDA values in the depressed group after treatment (increased levels of serotonin) 
were statistically different (0.607 nmol/gHb) still higher than control, but lower than 
those found in depressed patients. Although we are aware of the evolutionary gap 
between humans and Daphnia, this results can be read in line with ours since we did 
not find any difference in MDA content in D. magna treated with fluoxetine, but we 
observed a slight not significant decrease at the highest concentration.   
Regarding the oxidative effect of Cr(VI), Fabbri and Capuzzo (2006) detected a 
significant decrease in labilization time in lysosomes of the digestive glands of Mytilus 
galloprovincialis exposed to 10 µg/L chromium(VI) for 7 d. Decrease in labilization 
time, is considered an index of cellular damage and consequently, of stress. In the 
same conditions they found a significant increase in cAMP content in the gills. Jemec 
et al. (2008) observed a decrease in protein content in D. magna exposed for 21 
days to 1.1, 17.5, 52.5 µg/L of  chromium(VI), a reflection of the general detrimental 
effect physiological state of the organism. 
Moreover, we observed that at 0.2 mg/L Cr(VI), MDA content did not increase 
significantly in comparison with the control. Our hypothesis is that such high 
concentration inhibits many process, including peroxidation. This results is in line with 
the study by Jemec et al. (2008), who observed a significant increase in GST activity 
in D. magna exposed for 21 d at low concentration of Cr(VI), 0.52, 4.3, 17.5 µg/L, but 
they found values similar to the control for the highest concentration 52.5 µg/L Cr(VI). 
A further hypothesis is that at high concentration MDA, which is an intermediate 
product, decreases progressively increasing the lipofuscin production, in fact 
lipofuscins represent an end point in the lipid peroxidation process and their 
accumulation is easily detectable in cells of stressed organisms. When ROS levels 
production exceeds antioxidant defences, the peroxidation end-products are 
accumulated in lysosomes as insoluble granules containing autofluorescent pigments 
usually referred to as lipofuscins. The bulk of lipofuscin granules is constituted by 
oxidatively modified proteins and lipid degradation products, along with 
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carbohydrates and metals (Buratti, 2011). All lipofuscin pigments are not degradable. 
During the exposure of organisms to pollutants, this biomarker typically shows a 
continuously increasing trend, which reaches a maximum level that is determined by 
the rate of secretion of lipofuscin-rich residual bodies into the external fluids.  
 
To conclude, although MDA content was not different from the control in D. magna 
exposed to fluoxetine, it was significantly increased in D. magna exposed to 
chromium(VI). Since test on heavy metal has established that this biomarker is 
suitable for organisms as D. magna, we simply conclude that fluoxetine does not 
affect MDA content at  least at the tested concentrations. 
 
 
5.3.3 Gluthatione S-transferase  
 
GST activity in the control treatment was about 134 nmol/min/mg protein, while slight 
higher activities were observed in D. magna exposed to 1.0 and 5.0 mg/L fluoxetine, 
although the differences from the control were not statistically significant. These 
results were in line with the Jemec et al. (2007) study in which they observed control 
values similar to ours and no significant change in GST activity in D. magna exposed 
for 48 hours to up to 280 µg/L of Cr(VI) and up to 7 µg/L of diazinon (one of the most 
used insecticides). Although literature data on the effect of Cr(VI) on GST are 
inconsistent (Jemec et al., 2007), GST activity was expected to increase due to 
possible oxidative stress caused by Cr(VI) (Stohos and Bagchi, 1995). Also Choi 
(2000) did not observe any effect in Chironomus riparius  exposed to 1.75 mg/L for 
24 h. In another study, Barata et al. (2005) observed that GST activity increases in D. 
magna exposed for 48 h to five substances known to lead ROS production: cadmium 
(2, 5 µg/L), copper (5, 20 µg/L), the pesticides endosulfan (200, 400, 600 µg/L) and 
paraquat (2, 5 µg/L), and the quinine menadione (50, 200 µg/L). They observed also 
that organic substances induced greater GST activity stimulation than metals.  
Moreover, Jemec et al. (2008), during chronic 21 days test, observed a significant 
increase in GST activity in D. magna exposed at low concentration of Cr(VI) (0.52, 
4.3, 17.5 µg/L).  
Regarding the effect of fluoxetine on GST activity, as for the other biomarkers 
analyzed in this study, we do not have information about effect of fluoxetine in D. 
magna, thus we can only refer to fluoxetine effects in other organisms. In a recent 
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study Gonzales-Rey and Bebianno (2013) exposing mussels M. galloprovincialis to 
75 ng/L of fluoxetine up to 15 days, detected a similar GST activity in both tissues, 
gills and digestive glands, although with irregular patterns. In controls, GST activities 
in both tissues decreased; after the first week in gills and immediately after the 3rd 
day in digestive gland. In exposed mussels, GST activity remained unaltered in gills, 
whereas in digestive gland it fluctuates decreasing to control levels after the first 
week of exposure and varying to significantly higher activities than controls after the 
3rd and 15th day of exposure and increasing thereafter. Phase II detoxification 
enzyme GST promotes reduced glutathione (GSH) conjugation with parental 
electrophilic compounds enabling its transformation to more extractable hydrophilic 
metabolites (Halling-Sørensen et al., 1998).  
The above results on GST activities in D. magna after an acute exposure to organic 
substances or metal are discordant therefore further studies should be conducted. 
In the present investigation, GST activity was not increased by fluoxetine at the 
tested concentrations, although fluoxetine effects on GST activity was observed in M. 
galloprovincialis. We may conclude that D. magna does not counteract possible 
effects by fluoxetine through the detoxification system represented by GST, or at 
these concentrations fluoxetine does not affect the crustacean. As a whole, although 
other studies have reported antioxidant enzyme response in D. magna, accurate 
information on antioxidant defense system against contaminants are absent. 
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6. Conclusion 
 
 
The main aim of the present work was to evaluate alteration of life cycle endpoints on 
D. magna exposed to mixtures of propranolol and fluoxetine, two pharmaceuticals 
widely detected in freshwater environment. To gain further knowledge, also three 
widely used biomarkers were applied, i.e. acetylcholinesterase inhibition, MDA levels, 
and GST activity.   
The issue of pharmaceutical in the aquatic environment is of concern worldwide, and 
in the latest years received great attention within the scientific community. However, 
pharmaceutical residues are never alone in water, and their possible interaction when 
animals are exposed to mixtures is difficult to study and indeed rarely investigated. 
Mixture effects are indeed the most urgent topic requiring investigation in this field. 
The MixTox tool allowed the conclusion that an antagonistic effect was caused in 
Daphnia exposed to the mixtures, i.e. the effect of the mixture on immobilization and 
reproduction was lower than the effects of the two pharmaceuticals applied alone. 
Two different tests, acute and chronic were performed on D. magna, and both 
reached the above conclusion. This result is based on the choice of concentration 
addition as the reference model that defines the absence of interaction between the 
two chemicals. This, in turn, is founded on the assumption that the two 
pharmaceuticals share a common mode of action in Daphnia. 
Although, D. magna physiology is not known in details, this approach let us 
hypothesize that exposure to pharmaceutical mixtures also affected cell signaling, 
including cAMP, serotoninergic and adrenergic receptors, which suggest an 
evolutionary conservation of the basal biological targets between humans and 
crustaceans. According to this hypothesis, the involvement of cAMP is both the 
common element in the mode of action of fluoxetine and propranolol and the 
explanation for antagonism. 
Studying the early stress response with molecular biomarkers, no effect was detected 
in D. magna exposed to fluoxetine. Nevertheless, further analysis should be carried 
to search for early warning biomarkers in D. magna.  
Although pharmaceutical concentrations used during the study are much higher than 
the actual concentrations found in the environment, the research is not less 
important, and data obtained must be regarded as indications to be used in 
ecological risk assessment. In this regard, one of the major concerns is the possible 
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amplification of effects when multiple contaminants in particular, are present in the 
environment. In this particular case, the contrary was actually observed.  
More studies should be conducted to better investigate the physiology of D. magna 
and the effects of pharmaceutical mixtures, crucial for risk assessment approaches. 
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